

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029170
Article Type:	Protocol
Date Submitted by the Author:	15-Jan-2019
Complete List of Authors:	Nielsen, Suzanne; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre; UNSW Sydney, Crossin, Rose; Eastern Health Middleton, Melissa; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre Martin, Catherine; Monash University Wilson, James; Eastern Health Lam, Tina; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre Scott, Debbie ; Monash University Eastern Health Clinical School, Turning Point Smith, Karen; Ambulance Victoria, Centre for Research and Evaluation Lubman, D; Monash University, Turning Point
Keywords:	pharmaceutical opioids, ambulance attendance, extramedical use, overdose, oxycodone, tapentadol

SCHOLARONE™
Manuscripts

Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Suzanne Nielsen^{1,4}, Rose Crossin^{1,2,3}, Melissa Middleton¹, Catherine Martin⁵, James Wilson^{2,3}, Tina Lam^{1,2}, Debbie Scott^{1,2,3}, Karen Smith^{5,6,7} and Dan Lubman^{1,2,3}

¹ Monash Addiction Research Centre, Monash University, Frankston, VIC 3199

² Eastern Health Clinical School, Monash University, Box Hill, VIC 3128

³ Turning Point, Eastern Health, Richmond, VIC 3121

⁴ National Drug and Alcohol Research Centre, UNSW Sydney, Randwick, NSW 2031

⁵ Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC 3004

⁶ Ambulance Victoria, Doncaster, VIC 3108

⁷ Department of Community Emergency Health and Paramedic Practice, Monash University, Frankston, VIC 3199

Corresponding author:

A/Professor Suzanne Nielsen

Level 3 Building G, McMahons Road, Frankston, VIC 3199

suzanne.nielsen@monash.edu

+61 3 9904 4641

Word count: 3584

Declarations of competing interests

In the past 5 years, SN has been an investigator on untied education grants from Indivior, unrelated to the current work. SN has provided training to health care professionals on identifying and treating codeine dependence for which her institution has received payment from Indivior. DL has received speaking honoraria from the following: Astra Zeneca, Indivior, Janssen-Cilag, Lundbeck, Servier and Shire, and has participated on Advisory Boards for Indivior and Lundbeck.

Funding

The study is funded by an untied educational grant from Seqirus. SN is the recipient of an NHMRC Career Development Fellowship (#1163961). The funders will have no role in the study design, study conduct, analysis or data interpretation. Prior to publication, representatives from Seqirus will have the opportunity to review the manuscript and provide comment on factual inaccuracies, if identified.

Abstract

Introduction and aims: Extramedical use of, and associated harms with pharmaceutical opioids are common. Analysis of coded ambulance clinical records provides a unique opportunity to examine a national population-level indicator of relative harms. This protocol describes an observational study with three aims: (1) To compare supply-adjusted rates of pharmaceutical opioid-related ambulance attendances for, buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone, morphine, pethidine, tramadol and tapentadol; (2) to compare presentation characteristics for these commonly used pharmaceutical opioids; and (3) to describe the context surrounding ambulance presentations related to oxycodone, a widely used opioid with an established abuse liability, and tapentadol, a more recent ‘atypical’ opioid on the Australian market, with fewer studies that have directly examined signals of extramedical use.

Method: Trained coders extract data from clinical records for ambulance presentations relating to extramedical use of commonly used pharmaceutical opioids. This data forms the basis of a large, national database that captures alcohol and drug related harms. Supply adjusted rates of presentations will be examined using Poisson regression and multinomial logistic regression will be used to compare severity and other characteristics of attendances relating to different pharmaceutical opioids. Tapentadol-related and oxycodone-related cases will be qualitatively examined to understand the situationally-specific contexts of the ambulance attendances outside of the characteristics captured in routinely coded variables.

Ethics and dissemination: Ethics approval related to analysis of ambulance attendance data was obtained from the Eastern Health Human Research Ethics Committee (E122 08-09), with an amendment specific to the qualitative analysis. Findings will be submitted for peer review in 2019. The understanding of risk-profiles in real-world settings is of international public health importance. The analysis and publication of findings from this national dataset of clinical records will provide one of the most nuanced analyses to date of relative harms across nine pharmaceutical opioids over a seven-year period.

Keywords: pharmaceutical opioids, ambulance attendance, extramedical use, overdose, oxycodone, tapentadol

Article summary

- There are few studies which examine the relative harms associated with different pharmaceutical opioids
- This study will provide one of the most nuanced analyses to date of relative harms across nine pharmaceutical opioids across a seven-year period.

Strengths and limitations

- Strengths of this study include use of coded pharmaceutical opioid-related ambulance attendance data as validated population-level indicator of opioid-related harm such as extramedical use and overdose to inform risk profiles in real-world settings
- We will compare the supply-adjusted rates and characteristics of ambulance attendances with commonly used pharmaceutical opioids
- Limitations include the use of administrative data, and a lack of toxicological data to confirm substances taken

Introduction

Recently, the world's attention has focused on the rapidly escalating opioid-related deaths occurring in North America and other high-income countries (1). This has put into sharp focus the need to understand the risk profiles associated with different pharmaceutical opioids.

The number and potency of available pharmaceutical opioids has increased rapidly over the past decades. Morphine, a selective mu-opioid agonist, was isolated more than 200 years ago (2). Following this, analogues such as diamorphine and codeine were developed. Later, semi-synthetic opioids such as oxycodone (a full agonist at the mu-opioid receptor) and buprenorphine (a partial agonist at the mu-opioid receptor (with activity at delta and kappa) (3) were isolated. In addition, newer 'atypical' opioids such as tramadol and tapentadol exert their analgesic effects via opioid and non-opioid mechanisms (4). Tramadol, a lower potency mu opioid receptor agonist with a more potent metabolite, also selectively inhibits noradrenalin and serotonin uptake (5, 6). Tapentadol is another synthetic opioid, structurally similar to tramadol, with mu-opioid receptor agonism and inhibition of noradrenaline reuptake (7).

A United States (US) study of severe adverse events (SAEs) found a positive linear relationship between opioid potency and SAE rate, with the highest rate observed with hydromorphone (8.02 SAEs/100 kg), and the lowest rate with tapentadol (0.27 SAE/100 kg) (8). This suggests that harms related to opioids may not be equal, though replication studies outside the US are needed.

Abuse liability studies also find differences between prescribed opioids. Differences in the strength of reinforcing or subjective effects between tramadol, oxycodone, codeine have been found (9). Subjective effects of oxycodone appeared greater than codeine, though all opioids examined were reinforcing, particularly at higher doses (9). A separate study examined ratings of 'I feel high', and the amount that people were willing to pay for a drug varying by opioid type (10). Defined doses of diamorphine, morphine, and oxycodone had higher ratings than buprenorphine and fentanyl (10). In this study, oxycodone produced robust reinforcing effects, consistent with systematic review of nine studies that oxycodone had a higher abuse liability relative to other opioids (11).

Although abuse liability may vary in controlled laboratory studies, opioid use in real-world settings can vary as a function of cost, availability and other contextual factors (12). For this reason, pharmacovigilance studies are important to monitor for signals of extramedical use in real-world settings. Further, signals of extramedical use may only appear after trials, as those likely to use opioid

1
2
3 extramedically are often excluded from these studies, so data from diverse populations is important
4 (13).
5
6
7

8 Sentinel surveillance aims to assess nonmedical use and harms with opioids such as oxycodone and
9 morphine (14). For newer opioids, or opioids infrequently used by sentinel study populations,
10 population level studies can more completely assess for signals of extramedical use (15). One
11 population level indicator of opioid-related harm is ambulance attendances. These data are recognised
12 as a valuable data source for identifying population level signals of harm (16). In Australia, the
13 clinical records of ambulance attendances related to extramedical use of pharmaceuticals (i.e. use
14 outside a medical context, or in a higher dose than prescribed) are coded by trained research
15 assistants. These data can inform the risk profile with different pharmaceutical opioids (17), and has
16 been used to monitor harms related to quetiapine and pregabalin (18, 19). These data can determine if
17 unintended harms such as extramedical use and overdose are emerging, and provide information on
18 the frequency, severity and context of presentations.
19
20
21
22
23
24
25

26
27 As such, this paper outlines the design of a study that aims to conduct a detailed examination of
28 ambulance attendances related to pharmaceutical opioids, and test the hypothesis that the context and
29 frequency of harms with different opioids will vary by opioid type. We write this protocol to
30 maximize transparency (20, 21). The study is supported by an untied educational grant by Seqirus,
31 who make Palexia® (tapentadol) and Tramal® (tramadol). The funders have no role in the design,
32 conduct, analysis and interpretation of the study and its findings. As has been highlighted by others in
33 the field (22), prospectively publishing study protocols with primary aims and related analysis plans
34 assist in establishing independence around the study design, providing transparency, and ensuring a
35 commitment to publishing study findings regardless of the outcome (21).
36
37
38
39
40
41
42
43
44

45 Methods

46 Study aims

47 This study has three aims:

- 48 1) Compare the supply-adjusted rates of ambulance attendances across commonly used
49 pharmaceutical opioids (buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone,
50 morphine, pethidine, tramadol and tapentadol).
51
- 52 2) Compare presentation characteristics for these nine opioids.
53
- 54 3) Describe the context surrounding ambulance presentations related to two opioids: oxycodone,
55 a widely used opioid with an established abuse liability, and tapentadol, a newer opioid with
56 fewer studies describing extramedical use.
57
58
59
60

We will answer the following research questions:

1. Do the supply-adjusted rates of ambulance presentations differ by opioid potency?
2. Does the severity of presentation (as measured by presenting Glasgow Coma Scale, GCS) or other characteristics vary by opioid type?
3. Are there differences in the context surrounding ambulance presentations related to extramedical use of oxycodone and tapentadol?

Study design and setting

Data come from ambulance attendances in Victoria; a state which comprises approximately 26% of Australia's population (23), supplemented by national ambulance data. The Victorian dataset provides complete coverage across the study period (June 2013 until September 2018, excluding 3 months of missing data October - December 2014, due to industrial action). Coded electronic patient care records (ePCR) provide information on acute harms arising from extramedical pharmaceutical use, thus allowing comparison of attendance characteristics across multiple opioids.

We will examine data from the National Ambo Project from Queensland, New South Wales, Australian Capital Territory, Northern Territory and Tasmania to determine if Victorian trends are comparable to national trends. National data is available in quarterly 'snap-shot months' (Table 1) and are screened and coded using the same procedures and coders as the Victorian data.

Pharmaceutical opioid sales data

We will estimate the amount of each opioid supplied using monthly sales data (IQVIA third party access program). The total amount of each opioid will be calculated by jurisdiction in mg, converted into Oral Morphine Equivalents (OME) (24), and used to calculate a supply-adjusted rate of attendances.

Ambulance attendance data

Ambulance data are collected as part of the Ambo Project, a collaboration between Turning Point, Monash University and Ambulance Victoria (AV). Methods for the Ambo Project have been previously described (e.g. (18, 19)) and are outlined below.

Data includes electronic patient care records (ePCR), computer aided dispatch notes, and clinical details associated with the attendance that provide part of the patient care record (e.g. records of respiration rate and GCS). Primary filtering based on over-inclusive keyword searches identifies

1
2
3 attendances with involvement of alcohol, other drugs, or mental health symptomology. This filtered
4 dataset is provided to Turning Point where data cleaning, validation, and coding of the ePCR is
5 performed by a specialist team of research assistants. A systematic and validated coding system
6 captures information from the ePCR. The core criterion used in determining the involvement of a
7 substance is: "Is it reasonable to attribute the immediate or recent (not merely chronic) over- or
8 inappropriate (i.e. extramedical) ingestion of the substance or medication as significantly contributing
9 to the reason for the ambulance attendance?", as determined through examination of the clinical notes.
10 As such, this dataset captures information on acute, not chronic, harms.
11
12
13
14
15
16

17 For this study, ambulance attendances where extramedical pharmaceutical opioid use was identified
18 as a significant contributor to an attendance will be included. This dataset excludes cases of solely
19 therapeutic use. Pharmaceutical opioid-related attendances include those where; a person prescribed
20 opioids consumed medication more often or in higher than recommended amounts; a person
21 consumed opioids not prescribed to them, or if opioids were consumed with a combination of other
22 substances that contributed to the ambulance attendance. The inclusion criteria mean that
23 extramedical opioid use must significantly contribute to the attendance, however other drugs or
24 substances may have also been over- or inappropriately consumed, and the extramedical opioid use
25 may not be the primary or only reason for the ambulance attending. These criteria differentiate Ambo
26 Project data from adverse event reporting from the Therapeutic Goods Administration (TGA)
27 Database of Adverse Event (AE) Notifications (25), which captures spontaneous AEs from prescribed
28 medications. Spontaneous AE reporting can effectively identify serious harms with prescribed
29 medicines, though is recognised to miss the vast majority of AEs (26).
30
31
32
33
34
35
36
37
38
39

40 Other associated factors such as alcohol and other drug use, mental health symptoms, and self-harm
41 are also coded. All illicit drug use is coded, regardless of quantity. Current mental health
42 symptomology is coded rather than mental health diagnosis as paramedics do not screen or assess
43 mental illness diagnoses during an ambulance attendance.
44
45
46

47 These methods are consistent across other jurisdictions, which collect quarterly data as part of the
48 National Ambo Project, with the exception that ambulance services in Tasmania, Australian Capital
49 Territory, and the Northern Territory provide all data and do not undertake primary filtering.
50
51
52

53 All substances related to the attendance are coded; including alcohol, illicit & pharmaceutical drugs.
54 For this project, we will examine buprenorphine (as a single ingredient), codeine (codeine as a single
55 ingredient, and in combination with paracetamol, or ibuprofen, or aspirin), fentanyl, morphine,
56 oxycodone, oxycodone-naloxone, pethidine, tapentadol and tramadol. We will exclude opioids used
57 as treatments for opioid dependence (methadone, buprenorphine-naloxone, or buprenorphine and a
58
59
60

1
2
3 single ingredient where indicated that it is for treatment of opioid dependence) as these represent a
4 different clinical indication and specific treatment population.
5
6

7
8 Buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone, morphine, pethidine and
9 tramadol are routinely coded in the Ambo project database. Cases involving tapentadol are routinely
10 coded in an 'other opioid' category. For this study 'tapentadol-related' cases will be identified and
11 coded by reviewing all cases from June 2013 (aligned with tapentadol availability as a subsidised
12 medicine in Australia), until September 2018. This is identical to the coding process used with other
13 opioids, the only difference being that the cases will be coded retrospectively from 'other opioids' to
14 'tapentadol' where there is evidence of tapentadol involvement in the ePCR.
15
16
17
18
19

20 21 22 **Aim 1 – supply-adjusted trends 2013-2018**

23
24 Analysis of supply-adjusted trends will occur by quarterly aggregation of attendances in Victoria, by
25 opioid group, with further aggregation to half-yearly if required to preserve cell sizes of at least five in
26 the majority of cells. Where cell sizes of <5 occur, to preserve anonymity we will report average of all
27 cells with 1-4 cases, rather than the number of cases in that cell. Units will be attendances per 100
28 000mg OME (24).
29
30
31
32

33 *Aim 1 analysis plan*

34
35 Prescription opioid-related ambulance attendances will be aggregated into 3 monthly periods
36 corresponding to yearly quarters. Basic descriptive statistical analyses will be used to explore these
37 attendances in Victoria, analyses include frequencies (number of attendances), proportions
38 (demographics), and supply-adjusted rates.
39
40
41
42

43 Poisson regression will be used to assess trends in supply-adjusted rates for Victoria. Regression
44 models will be fitted (one for each opioid), and adjusted for quarterly and yearly trends with the
45 number of days per month used to offset the regression. Rates will be calculated for Victoria (where
46 completed data are available), and compared with rates observed in other states for the time periods
47 that data are available (Table 1). Due to industrial action, September 2014 contains partially complete
48 data (26 out of 30 days). Supply data for this month will be weighted to represent the average supply
49 for the proportion of days provided for September, with the offset variable representing the total
50 number of days where data has been supplied.
51
52
53
54
55

56
57 The intention is to assess trends within each opioid where the opioid has been solely indicated, as well
58 as a 'multiple opioid' category representing cases where multiple opioids have been indicated.
59
60

1
2
3 However, where this is not possible due to small case numbers, trends will be assessed using all cases
4 in which the opioid has been indicated (sole use and multiple opioids).
5
6
7

8 **Aim 2 – characteristics of attendances**

9 For this analysis, opioid-related attendances will be analysed by opioid type listed above, by
10 characteristics as per Table 2.
11
12
13

14 *Aim 2 analysis plan*

15
16 Multinomial logistic regression will be used to analyse characteristics of opioid-related attendances by
17 opioid type. Opioid type (sole use of each opioid and multiple opioid use) will be used as the
18 dependant variable, with each category being compared to morphine as mid-potency opioid, regressed
19 on each characteristic separately. If the number of morphine cases is insufficient to allow use as a
20 reference category then oxycodone will become the reference category. Each model will be adjusted
21 for using a collapsed state variable (where jurisdictions with expected fewer cases such as the
22 Australian Capital Territory and Northern Territory will be aggregated into an ‘other states’ category).
23 When considering GCS as a proxy for severity, the model will be further adjusted for age, gender,
24 concurrent alcohol use, concurrent illicit drug use (excluding heroin), concurrent heroin use, and
25 concurrent non-opioid pharmaceutical use. All other models will be further adjusted for age, gender
26 and other substance use (as an aggregated variable of concurrent alcohol use, illicit drug use, heroin,
27 and non-opioid pharmaceutical misuse). Results will be reported as odds ratios. Comparison between
28 states will be analysed through an interaction between state and characteristic.
29
30
31
32
33
34
35
36
37
38
39

40 **Aim 3 – qualitative analysis of contexts of oxycodone and tapentadol-related attendances**

41 Detail from the free-text fields from the ePCR will be utilised to establish a more complete picture of
42 the ambulance attendance. These data are subject to rigorous coding by a highly trained team of
43 coders using well-established and tested coding frameworks for existing fields, however additional
44 uncoded data are available in these free-text fields are rarely used for qualitative analyses. Some
45 studies have used text-based information to explore specific phenomena in further detail, such as
46 intentional and unintentional injury (27) and heroin overdose (28).
47
48
49
50

51 We will use text-based case descriptions of oxycodone-related and tapentadol-related cases. These
52 will be qualitatively examined in order to provide insight into the situationally-specific contexts of the
53 ambulance attendances outside of the characteristics captured in routinely coded variables. We will
54 compare tapentadol-related cases (with tapentadol being a newer ‘atypical’ opioid with a suggested
55 lower rate of associated adverse events (8) and less non-medical use (29)), to oxycodone-related
56 attendances, as oxycodone is the predominant opioid-analgesic prescribed in Australia (30) and has a
57
58
59
60

1
2
3 well-recognised abuse liability (11). We will consider the details of circumstances surrounding the
4 presentation including details provided on the role and effect of the opioid used.
5
6

7 *Aim 3 analysis plan*

8
9 Qualitative coding will occur in two stages. First, an initial group of randomly selected cases
10 (estimated n=30-40 until saturation has occurred) will be examined by two researchers to
11 independently determine a coding framework. The researchers will negotiate a consensus framework,
12 then code the remaining cases using this agreed upon framework. The project team will convene
13 regularly to discuss coding techniques as they develop as well as emerging themes. A 10% sample of
14 cases will be checked by a third researcher to confirm coding consistency, with further cases reviewed
15 if inconsistencies are identified.
16
17
18
19

20
21 We will examine an equal number of tapentadol- and oxycodone-related cases, based on the number
22 of cases identified for tapentadol (the less frequently used opioid). We will use a random number
23 generator via Excel to randomly select an equal size number of oxycodone-related cases for
24 qualitative comparison (i.e. the same number of cases as in the tapentadol-related case group), and
25 perform the same analyses for oxycodone-related presentations. To ensure that selected oxycodone
26 cases represent all oxycodone cases the sub-group of oxycodone-related attendances will be selected
27 by weighted random sampling, with weightings on the basis of sex, age group, jurisdiction and if the
28 attendance was related to self-harm. Cases involving both tapentadol and oxycodone will be
29 considered as a separate group.
30
31
32
33
34
35

36
37 In addition to qualitative analysis, multinomial regression will be used to analyse coded variables
38 representing different aspects of attendance context surrounding three mutually exclusive groups: (1)
39 tapentadol-related cases, (2) oxycodone-related cases, and (3) cases that are related to the concomitant
40 use of tapentadol and oxycodone (i.e. considered-related to both opioids). Results will be reported as
41 odds ratios.
42
43
44
45

46
47 All quantitative analysis for aims 1-3 will be conducted in STATA (StataCorp. 2013. Stata Statistical
48 Software: Release 13. College Station, TX: StataCorp LP), with p values less than 0.05 considered
49 significant. Qualitative data will be managed and analysed using nVivo 12.0 (31), but any subsequent
50 quantitative analyses conducted using STATA as above.
51
52
53

54 *Handling known or expected missing data*

55
56 Where there are missing data for the characteristics of attendances, we will report the available
57 sample size for each variable. To enable calculation of rates for each quarter with potentially
58 identifiable cases (cell size 1-4), we will impute a value representing the mean for all potentially
59
60

1
2
3 identifiable cases. This will preserve the total number of cases without compromising privacy of
4 individuals.
5
6
7

8 There are three months of missing Victorian data due to industrial action (October – December 2014)
9 with partial missing data (4 days) for September 2014. For these months, to enable calculation of rates
10 (Aim 1), we will impute values based on data from September – December in the previous and
11 following year (2013 and 2015). In a planned sensitivity analysis, we will compare results using
12 imputed data to results excluding missing data and report any differences observed.
13
14
15
16

17 Ethics and dissemination

18 Ethics approval related to analysis of ambulance attendance data was obtained from the Eastern
19 Health Human Research Ethics Committee (E122 08-09), with an amendment specific to the
20 qualitative analysis. Consistent with the ethics approval, cells of <5 will not be reported, though
21 zeroes will be preserved. Due to the sensitivity and potentially identifiable nature of the data line item
22 data is not available for sharing, consistent with the ethics approval.
23
24
25
26
27

28 We will present project findings at relevant scientific conferences. We plan to submit findings for
29 publication as two peer-reviewed journal articles. One article will incorporate the quantitative analysis
30 (aim 1 and 2) and one paper report the qualitative analysis (aim 3). We will report findings in
31 accordance with the REporting of studies Conducted using Observational Routinely-collected health
32 Data (RECORD) statement, an extension of the STROBE statement for reporting items specific to
33 observational studies using routinely collected health data (32).
34
35
36
37
38
39
40

41 Discussion

42 Strengths and limitations

43 Recommendations for methods for pharmacovigilance studies identified a number of important
44 features, depending on the aims of the study and the methods employed (16). These include the
45 prospective publication of a study protocol including a detailed statistical analysis plan, transparency
46 around study funding and publication in open-access journals. This study will conform to these
47 requirements.
48
49
50
51
52
53
54

55 This study has several strengths. Firstly, coded ambulance data captures a broader range of outcomes
56 and a wider population of people with extramedical pharmaceutical opioid use than may be captured
57 in abuse liability studies, clinical trials, or spontaneous AE reporting systems.
58
59
60

1
2
3
4
5 Secondly, this study's population level database accurately codes detailed information about each
6 attendance. This level of detail can provide important insights into harms related to substance use (17-
7 19, 33-35). This study will represent an extension of these studies to provide a detailed analysis of
8 rates and characteristics of harms related with widely used pharmaceutical opioids, and is
9 strengthened by the use of population level supply data to calculate supply-adjusted rates. Finally, the
10 study will be first to provide detailed context around circumstances of pharmaceutical opioid related
11 ambulance attendances, utilising coding of qualitative data.
12
13
14
15

16
17 There are limitations in the use of data collected for operational purposes, similar to with hospital
18 inpatient and emergency department data. There is potential for biases to exist in collection and
19 coding, and incomplete or inconsistent recording of variables. Substance involvement is determined
20 from patient-provided information, others at the scene, or paramedic's clinical assessment, not from
21 toxicological testing. Other clinical details (e.g. mental health symptoms) are also determined in this
22 way.
23
24
25
26
27

28 Rates of ambulance attendances are calculated based on sales data. Due to frequent ordering and
29 limited capacity for controlled drug storage at the community pharmacy level, sales closely
30 approximate supply. Use of sales data addresses limitations with publicly funded prescription data,
31 which omits privately purchased prescriptions and over-the-counter medications and therefore is an
32 incomplete measure of community opioid supply. Finally, as this is a naturalistic study, we cannot
33 know if different patient populations are more likely to receive a given opioid. As such, there may be
34 unmeasured confounders. Randomised trials can address this limitation; however, patients who use
35 opioids extramedically are usually excluded from trials.
36
37
38
39
40
41
42

43 Data statement

44
45 To protect privacy and confidentiality, data from the Ambo Project are provided to Turning Point
46 under strict conditions for the storage, retention and use of the data. The current approval permits
47 storage of the data at one site, Turning Point, with any analysis to be undertaken onsite, no data to be
48 removed, and no dissemination of unit level data. Researchers wishing to undertake additional
49 analyses of the data are invited to contact Turning Point as the data custodians.
50
51
52
53
54

55 Conclusion

1
2
3 This will be the first detailed study to compare coded ambulance ePCR as a population level indicator
4 of prescription opioid-related harm. These data will complement ongoing studies examining
5 extramedical use of tapentadol in sentinel populations of people who use drugs, and data from poisons
6 information centres (36). The data in this study represent all acute presentations in community settings
7 where extramedical use of a pharmaceutical opioid analgesic is considered related to the ambulance
8 attendance. This unique dataset has national reach and demonstrated consistency and completeness
9 over multiple years. It will provide one of the most complete analyses of relative harms due to
10 extramedical use for a range of pharmaceutical opioids to date. The study will add to our knowledge,
11 and lead to a more nuanced understanding of whether different pharmaceutical opioids are associated
12 with different harms.
13
14
15
16
17
18
19

20 Acknowledgements

21 We acknowledge Sharon Matthews and the population health team of coders who code the data, and
22 the ambulance services around Australia who provide the data.
23
24
25

26 Author statement

27 SN conceptualised the study and drafted the initial design, with input from RC and DS. CW and MM
28 provided input on the data analysis plan. All authors contributed the drafting of the protocol
29 manuscript and revisions.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2018;18(6):1556-68.
2. Krishnamurti C, Rao SC. The isolation of morphine by Serturmer. *Indian journal of anaesthesia*. 2016;60(11):861-2.
3. Pasternak GW, Pan Y-X. Mu opioids and their receptors: evolution of a concept. *Pharmacological reviews*. 2013;65(4):1257-317.
4. Pergolizzi JV, LeQuang JA, Taylor R, Ossipov MH, Colucci D, Raffa RB. Designing safer analgesics: a focus on μ -opioid receptor pathways. *Expert Opinion on Drug Discovery*. 2018;13(10):965-72.
5. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in Tramadol: Pharmacology, Metabolism, and Misuse. *Anesthesia and analgesia*. 2017;124(1):44-51.
6. Bravo L, Mico JA, Berrocoso E. Discovery and development of tramadol for the treatment of pain. *Expert Opinion on Drug Discovery*. 2017;12(12):1281-91.
7. Vadivelu N, Timchenko A, Huang Y, Sinatra R. Tapentadol extended-release for treatment of chronic pain: a review. *Journal of pain research*. 2011;4:211-8.
8. Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics. *Drug Saf*. 2018;41(8):787-95.
9. Babalonis S, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL. Abuse liability and reinforcing efficacy of oral tramadol in humans. *Drug and alcohol dependence*. 2013;129(1-2):116-24.
10. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2008;33(5):1179-91.
11. Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. *Journal of medical toxicology : official journal of the American College of Medical Toxicology*. 2012;8(4):335-40.
12. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the united states: A retrospective analysis of the past 50 years. *JAMA psychiatry*. 2014;71(7):821-6.
13. Turk DC, O'Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, et al. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. *Pain*. 2012;153(10):1997-2008.
14. Peacock AG, D., Sutherland, R., Uporova, J., Karlsson, A., Bruno, R., Dietze, P., Lenton, S., Alati, R., Degenhardt, L., & Farrell, M. Australian Drug Trends 2018. Key findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney, . National Drug and Alcohol Research Centre, UNSW Australia.; 2018.
15. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®). *Pain Medicine*. 2007;8(2):157-70.
16. Peacock A, Larance B, Bruno R, Pearson SA, Buckley NA, Farrell M, et al. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. *Addiction*. 2018.

17. Nielsen S, Dietze P, Lee N, Cantwell K, Taylor D. Methadone and Buprenorphine related ambulance attendances: A population-based indicator of adverse events. *Journal of Substance Abuse Treatment*. 2008;35(4):457-61.
18. Heilbronn C, Lloyd B, McElwee P, Eade A, Lubman DI. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. *Drug Alcohol Rev*. 2013;32(4):405-11.
19. Crossin R, Scott, D., Arunogiri, S., Smith, K., Dietze, P. M., & Lubman, D. I. Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. . *Medical Journal of Australia*. 2018;In press.
20. Editors PLoS Medicine. Observational studies: getting clear about transparency. *PLoS Medicine*. 2014;11(8):e1001711-e.
21. West R. Trial protocols. *Addiction*. 2012;107(9):1544-.
22. Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. *Addiction*. 2015;110(2):226-37.
23. Australian Bureau of Statistics. 3101.0 - Australian Demographic Statistics, Mar 2018. Accessed from: <http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0>. 20018.
24. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. . *Pharmacoepidemiology and Drug Safety*. 2016;25(6):733-7.
25. Therapeutic Goods Administration. Database of Adverse Event Notifications – medicines. Canberra. 2018.
26. Murff HJ, Patel VL, Hripcsak G, Bates DW. Detecting adverse events for patient safety research: a review of current methodologies. *Journal of Biomedical Informatics*. 2003;36(1):131-43.
27. Backe SN, Andersson R. Monitoring the “tip of the iceberg”: Ambulance records as a source of injury surveillance. *Scandinavian Journal of Public Health*. 2008;36(3):250-7.
28. Bammer G, Ostini R, Sengoz A. Using ambulance service records to examine nonfatal heroin overdoses. *Australian journal of public health*. 1995;19(3):316-7.
29. Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. *Pain Med*. 2015;16(1):119-30.
30. Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. *Pharmacoepidemiology and Drug Safety*. 2016;25(5):521-38.
31. Bazeley P, Jackson K. *Qualitative Data Analysis with NVivo* (2nd ed.). London: Sage; 2013.
32. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Medicine*. 2015;12(10):e1001885-e.
33. Lloyd BK, McElwee PR. Trends over time in characteristics of pharmaceutical drug-related ambulance attendances in Melbourne. *Drug and Alcohol Review*. 2011;30(3):271-80.
34. Dietze P, Jolley D, Cvetkovski S, Cantwell K, Jacobs I, Indig D. Characteristics of non-fatal opioid overdoses attended by ambulance services in Australia. *Aust N Z J Public Health*. 2004;28(6):569-75.
35. Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. *Med J Aust*. 2008;188(12):709-11.

1
2
3 36. Peacock A, Larance B, Farrell M, Cairns R, Buckley N, Degenhardt L. Opioid use
4 and harms associated with a sustained-release tapentadol formulation: a postmarketing study
5 protocol. BMJ Open. 2018;8(3):e020006.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Summary of data availability across jurisdictions

State / Territory	Notes on data available [^]
ACT	All cases coded one month per quarter from March 2015 until December 2017
NSW	All cases coded one month per quarter from March 2015 until December 2017
NT	All cases coded one month per quarter from March 2016 until December 2017
QLD	All cases coded one month per quarter from March 2015 until December 2016
TAS	All cases coded one month per quarter from March 2014, until December 2017
VIC	All cases coded from January 2012 till September 2018
WA & SA	Data not yet available

[^] We will conduct a comparison on supply-adjusted rates of attendance for Victoria and other states utilising periods of time where corresponding data are available.

For peer review only

Table 2. Variables and response options to be examined in association with pharmaceutical opioid-related ambulance attendances

Variable	Response options
Presenting Glasgow Coma Scale (GCS)	3 (non-responsive), 4-12 (moderate-severe impairment), 13-15 (minor-no impairment)
Presenting respiratory rate (breaths per minute)	<6, 6-12, >12
Transport to hospital	Not transported, transported
Naloxone administered: not stated, yes	Not stated, yes
Naloxone response: not effective, effective	Not effective, effective
Sex of patient	Male, female, other/unspecified
Age of patient	12-54, 55-65 (nearing retirement age) and 65+ [^]
Socio-economic status based on residential postcode	Quintile 1-5 based on SEIFA-IRSD 201s, IRSD 2016 (30)
Concurrent alcohol involvement	Not stated, alcohol involved but no evidence of intoxication, alcohol intoxication [∞]
Concurrent heroin involvement	Not stated, present
Concurrent illicit drug use (excluding heroin)	based on the presence of at least one of the illicit drugs coded for; meth(amphetamine), cannabis, synthetic cannabinoids, emerging psychoactive substances, cocaine, MDMA, GHB, ketamine, LSD, psilocybin, inhalant, illicit drug other or unspecified)
Concurrent non-opioid extramedical pharmaceutical use	not stated, present (based on the presence of at least one of the pharmaceutical groups coded for; non-opioid analgesics, benzodiazepines, anti-depressants, anti-psychotics, anti-convulsants, opioid-dependence treatments, pharmaceutical stimulants, other medication)
Co-morbid mental health symptoms	not stated, present (based on the presence of at least one of; symptoms of anxiety, depression, psychosis, social / emotional distress, symptoms associated with disorders with clinical evidence, and mental health unspecified)
Co-morbid suicidal thoughts or behaviours	Not stated, present (based on the presence of at least one of; suicidal ideation, suicide ats, suicide attempt)
Co-morbid non-suicidal self-injury	Not stated, present (based on the presence of at least one of; threat of non-suicidal self-injury, non-suicidal self-is, non-suicidal self-injury)
Accidental overdose	Not stated, yes
Unknown intent overdose [#]	Not stated, yes
Past history of psychiatric issues	Not stated, present (based on the presence of at least one of; past history of mood disorder, psychosis, suicidal ideation, suicide attempt, alcohol and other drug misuse)
[^] based on previous age categories used in studies of opioid use for pain (27). We will exclude cases where age is reported to be less than 12 due to the unclear intention of use in children of this age, consistent with previous research (28, 29) [#] (where information provided in the patient care records by the paramedic means that the coding team cannot determine if the overdose was accidental or if there was suicidal intent) [∞] The involvement of alcohol is coded as 'alcohol involved' and 'alcohol intoxication'. Attendances where the person has consumed alcohol, but the paramedic notes do not clearly indicate alcohol intoxication are coded as 'alcohol involved' and 'alcohol intoxication is a subset of 'alcohol involved'. The default code is for 'alcohol involved' unless the paramedic notes provide clear evidence of alcohol intoxication.	

BMJ Open

Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029170.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Mar-2019
Complete List of Authors:	Nielsen, Suzanne; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre; UNSW Sydney, Crossin, Rose; Eastern Health Middleton, Melissa; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre Martin, Catherine; Monash University Wilson, James; Eastern Health Lam, Tina; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre Scott, Debbie ; Monash University Eastern Health Clinical School, Turning Point Smith, Karen; Ambulance Victoria, Centre for Research and Evaluation Lubman, D; Monash University, Turning Point
Primary Subject Heading:	Addiction
Secondary Subject Heading:	Public health
Keywords:	pharmaceutical opioids, ambulance attendance, extramedical use, overdose, oxycodone, tapentadol

SCHOLARONE™
Manuscripts

Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Suzanne Nielsen^{1,4}, Rose Crossin^{1,2,3}, Melissa Middleton¹, Catherine Martin⁵, James Wilson^{2,3}, Tina Lam^{1,2}, Debbie Scott^{1,2,3}, Karen Smith^{5,6,7} and Dan Lubman^{1,2,3}

¹ Monash Addiction Research Centre, Monash University, Frankston, VIC 3199

² Eastern Health Clinical School, Monash University, Box Hill, VIC 3128

³ Turning Point, Eastern Health, Richmond, VIC 3121

⁴ National Drug and Alcohol Research Centre, UNSW Sydney, Randwick, NSW 2031

⁵ Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC 3004

⁶ Ambulance Victoria, Doncaster, VIC 3108

⁷ Department of Community Emergency Health and Paramedic Practice, Monash University, Frankston, VIC 3199

Corresponding author:

A/Professor Suzanne Nielsen

Level 3 Building G, McMahons Road, Frankston, VIC 3199

suzanne.nielsen@monash.edu

+61 3 9904 4641

Word count: 3678

Declarations of competing interests

In the past 5 years, SN has been an investigator on untied education grants from Indivior, unrelated to the current work. SN has provided training to health care professionals on identifying and treating codeine dependence for which her institution has received payment from Indivior. DL has received speaking honoraria from the following: Astra Zeneca, Indivior, Janssen-Cilag, Lundbeck, Servier and Shire, and has participated on Advisory Boards for Indivior and Lundbeck.

Funding

The study is funded by an untied educational grant from Seqirus. SN is the recipient of an NHMRC Career Development Fellowship (#1163961). The funders will have no role in the study design, study conduct, analysis or data interpretation. Prior to publication, representatives from Seqirus will have the opportunity to review the manuscript and provide comment on factual inaccuracies, if identified.

Abstract

Introduction and aims: Extramedical use of, and associated harms with pharmaceutical opioids are common. Analysis of coded ambulance clinical records provides a unique opportunity to examine a national population-level indicator of relative harms. This protocol describes an observational study with three aims: (1) To compare supply-adjusted rates of pharmaceutical opioid-related ambulance attendances for, buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone, morphine, pethidine, tramadol and tapentadol; (2) to compare presentation characteristics for these commonly used pharmaceutical opioids; and (3) to describe the context surrounding ambulance presentations related to oxycodone, a widely used opioid with an established abuse liability, and tapentadol, a more recent ‘atypical’ opioid on the Australian market, with fewer studies that have directly examined signals of extramedical use.

Method: Trained coders extract data from clinical records for ambulance presentations relating to extramedical use of commonly used pharmaceutical opioids. This data forms the basis of a large, national database that captures alcohol and drug related harms. Supply adjusted rates of presentations will be examined using Poisson regression and multinomial logistic regression will be used to compare severity and other characteristics of attendances relating to different pharmaceutical opioids. Tapentadol-related and oxycodone-related cases will be qualitatively examined to understand the situationally-specific contexts of the ambulance attendances outside of the characteristics captured in routinely coded variables.

Ethics and dissemination: Ethics approval related to analysis of ambulance attendance data was obtained from the Eastern Health Human Research Ethics Committee (E122 08-09), with an amendment specific to the qualitative analysis. Findings will be submitted for peer review in 2019. The understanding of risk-profiles in real-world settings is of international public health importance. The analysis and publication of findings from this national dataset of clinical records will provide one of the most nuanced analyses to date of relative harms across nine pharmaceutical opioids over a seven-year period.

Keywords: pharmaceutical opioids, ambulance attendance, extramedical use, overdose, oxycodone, tapentadol

Article summary

Strengths and limitations

- Strengths of this study include use of coded pharmaceutical opioid-related ambulance attendance data as validated population-level indicator of opioid-related harm such as extramedical use and overdose to inform risk profiles in real-world settings
- We will compare the supply-adjusted rates and characteristics of ambulance attendances with commonly used pharmaceutical opioids
- Limitations include the use of administrative data, and a lack of toxicological data to confirm substances taken

For peer review only

Introduction

Recently, the world's attention has focused on the rapidly escalating opioid-related deaths occurring in North America and other high-income countries (1). This has put into sharp focus the need to understand the risk profiles associated with different pharmaceutical opioids.

The number and potency of available pharmaceutical opioids has increased rapidly over the past decades. Morphine, a selective mu-opioid agonist, was isolated more than 200 years ago (2). Following this, analogues such as diamorphine and codeine were developed. Later, semi-synthetic opioids such as oxycodone (a full agonist at the mu-opioid receptor) and buprenorphine (a partial agonist at the mu-opioid receptor (with activity at delta and kappa) (3) were isolated. In addition, newer 'atypical' opioids such as tramadol and tapentadol exert their analgesic effects via opioid and non-opioid mechanisms (4). Tramadol, a lower potency mu opioid receptor agonist with a more potent metabolite, also selectively inhibits noradrenalin and serotonin uptake (5, 6). Tapentadol is another synthetic opioid, structurally similar to tramadol, with mu-opioid receptor agonism and inhibition of noradrenaline reuptake (7).

A United States (US) study of severe adverse events (SAEs) found a positive linear relationship between opioid potency and SAE rate, with the highest rate observed with hydromorphone (8.02 SAEs/100 kg), and the lowest rate with tapentadol (0.27 SAE/100 kg) (8). This suggests that harms related to opioids may not be equal, though replication studies outside the US are needed.

Abuse liability studies also find differences between prescribed opioids. Differences in the strength of reinforcing or subjective effects between tramadol, oxycodone, codeine have been found (9). Subjective effects of oxycodone appeared greater than codeine, though all opioids examined were reinforcing, particularly at higher doses (9). A separate study examined ratings of 'I feel high', and the amount that people were willing to pay for a drug varying by opioid type (10). Defined doses of diamorphine, morphine, and oxycodone had higher ratings than buprenorphine and fentanyl (10). In this study, oxycodone produced robust reinforcing effects, consistent with systematic review of nine studies that oxycodone had a higher abuse liability relative to other opioids (11).

Although abuse liability may vary in controlled laboratory studies, opioid use in real-world settings can vary as a function of cost, availability and other contextual factors (12). For this reason, pharmacovigilance studies are important to monitor for signals of extramedical use in real-world settings. Further, signals of extramedical use may only appear after trials, as those likely to use opioid

1
2
3 extramedically are often excluded from these studies, so data from diverse populations is important
4 (13).
5
6
7

8 Sentinel surveillance aims to assess nonmedical use and harms with opioids such as oxycodone and
9 morphine (14). For newer opioids, or opioids infrequently used by sentinel study populations,
10 population level studies can more completely assess for signals of extramedical use (15). One
11 population level indicator of opioid-related harm is ambulance attendances. These data are recognised
12 as a valuable data source for identifying population level signals of harm (16). In Australia, the
13 clinical records of ambulance attendances related to extramedical use of pharmaceuticals (i.e. use
14 outside a medical context, or in a higher dose than prescribed) are coded by trained research
15 assistants. These data can inform the risk profile with different pharmaceutical opioids (17), and has
16 been used to monitor harms related to quetiapine and pregabalin (18, 19). These data can determine if
17 unintended harms such as extramedical use and overdose are emerging, and provide information on
18 the frequency, severity and context of presentations.
19
20
21
22
23
24
25

26
27 As such, this paper outlines the design of a study that aims to conduct a detailed examination of
28 ambulance attendances related to pharmaceutical opioids, and test the hypothesis that the context and
29 frequency of harms with different opioids will vary by opioid type. We write this protocol to
30 maximize transparency (20, 21). The study is supported by an untied educational grant by Seqirus,
31 who make Palexia® (tapentadol) and Tramal® (tramadol). The funders have no role in the design,
32 conduct, analysis and interpretation of the study and its findings. As has been highlighted by others in
33 the field (22), prospectively publishing study protocols with primary aims and related analysis plans
34 assist in establishing independence around the study design, providing transparency, and ensuring a
35 commitment to publishing study findings regardless of the outcome (21).
36
37
38
39
40
41
42
43
44

45 Methods

46 Study aims

47 This study has three aims:
48

- 49 1) Compare the supply-adjusted rates of ambulance attendances across commonly used
50 pharmaceutical opioids (buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone,
51 morphine, pethidine, tramadol and tapentadol).
52
- 53 2) Compare presentation characteristics for these nine opioids.
54
- 55 3) Describe the context surrounding ambulance presentations related to two opioids: oxycodone,
56 a widely used opioid with an established abuse liability, and tapentadol, a newer opioid with
57 fewer studies describing extramedical use.
58
59
60

We will answer the following research questions:

1. Do the supply-adjusted rates of ambulance presentations differ by opioid potency?
2. Does the severity of presentation (as measured by presenting Glasgow Coma Scale, GCS) or other characteristics vary by opioid type?
3. Are there differences in the context surrounding ambulance presentations related to extramedical use of oxycodone and tapentadol?

Study design and setting

Data come from ambulance attendances in Victoria; a state which comprises approximately 26% of Australia's population (23), supplemented by national ambulance data. The Victorian dataset provides complete coverage across the study period (June 2013 until September 2018, excluding 3 months of missing data October - December 2014, due to industrial action). Coded electronic patient care records (ePCR) provide information on acute harms arising from extramedical pharmaceutical use, thus allowing comparison of attendance characteristics across multiple opioids.

We will examine data from the National Ambo Project from Queensland, New South Wales, Australian Capital Territory, Northern Territory and Tasmania to determine if Victorian trends are comparable to national trends. National data is available in quarterly 'snap-shot months' (Table 1) and are screened and coded using the same procedures and coders as the Victorian data. See Figure 1 for an overview of data sources and study processes. We will aim to complete case identification by March 2017, with analyses planned for March-April 2019.

Pharmaceutical opioid sales data

We will estimate the amount of each opioid supplied using monthly sales data (IQVIA third party access program). The total amount of each opioid will be calculated by jurisdiction in mg, converted into Oral Morphine Equivalents (OME) (24), and used to calculate a supply-adjusted rate of attendances, consistent with previous studies of pharmaceutical opioid related harm that have adjusted for supply using similar methods (8, 25).

Ambulance attendance data

Ambulance data are collected as part of the Ambo Project, a collaboration between Turning Point, Monash University and Ambulance Victoria (AV). Methods for the Ambo Project have been previously described (e.g. (18, 19)) and are outlined below.

1
2
3 Data includes electronic patient care records (ePCR), computer aided dispatch notes, and clinical
4 details associated with the attendance that provide part of the patient care record (e.g. records of
5 respiration rate and GCS). Primary filtering based on over-inclusive keyword searches identifies
6 attendances with involvement of alcohol, other drugs, or mental health symptomology. This filtered
7 dataset is provided to Turning Point where data cleaning, validation, and coding of the ePCR is
8 performed by a specialist team of research assistants. Details on research assistant training, and
9 interrater review processes are contained in Supplementary files (Appendix A). A systematic and
10 validated coding system captures information from the ePCR. The core criterion used in determining
11 the involvement of a substance is: "Is it reasonable to attribute the immediate or recent (not merely
12 chronic) over- or inappropriate (i.e. extramedical) ingestion of the substance or medication as
13 significantly contributing to the reason for the ambulance attendance?", as determined through
14 examination of the clinical notes. As such, this dataset captures information on acute, not chronic,
15 harms.

16
17
18
19
20
21
22
23
24
25 For this study, ambulance attendances where extramedical pharmaceutical opioid use was identified
26 as a significant contributor to an attendance will be included. This dataset excludes cases of solely
27 therapeutic use. Pharmaceutical opioid-related attendances include those where; a person prescribed
28 opioids consumed medication more often or in higher than recommended amounts; a person
29 consumed opioids not prescribed to them, or if opioids were consumed with a combination of other
30 substances that contributed to the ambulance attendance. The inclusion criteria mean that
31 extramedical opioid use must significantly contribute to the attendance, however other drugs or
32 substances may have also been over- or inappropriately consumed and the extramedical opioid use
33 may not be the primary or only reason for the ambulance attending. These criteria differentiate Ambo
34 Project data from adverse event reporting from the Therapeutic Goods Administration (TGA)
35 Database of Adverse Event (AE) Notifications (26), which captures spontaneous AEs from prescribed
36 medications. Spontaneous AE reporting can effectively identify serious harms with prescribed
37 medicines, though is recognised to miss the vast majority of AEs (27).

38
39
40
41
42
43
44
45
46
47 Other associated factors such as alcohol and other drug use, mental health symptoms, and self-harm
48 are also coded. All illicit drug use is coded regardless of quantity. Current mental health
49 symptomology is coded rather than mental health diagnosis as paramedics do not screen or assess
50 mental illness diagnoses during an ambulance attendance.

51
52
53
54
55 These methods are consistent across other jurisdictions, which collect quarterly data as part of the
56 National Ambo Project, with the exception that ambulance services in Tasmania, Australian Capital
57 Territory, and the Northern Territory provide all data and do not undertake primary filtering.

1
2
3 All substances related to the attendance are coded; including alcohol, illicit & pharmaceutical drugs.
4 For this project, we will examine buprenorphine (as a single ingredient), codeine (codeine as a single
5 ingredient, and in combination with paracetamol, or ibuprofen, or aspirin), fentanyl, morphine,
6 oxycodone, oxycodone-naloxone, pethidine, tapentadol and tramadol. We will exclude opioids used
7 as treatments for opioid dependence (methadone, buprenorphine-naloxone, or buprenorphine and a
8 single ingredient where indicated that it is for treatment of opioid dependence) as these represent a
9 different clinical indication and specific treatment population.
10
11
12
13
14

15
16 Buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone, morphine, pethidine and
17 tramadol are routinely coded in the Ambo project database. Cases involving tapentadol are routinely
18 coded in an 'other opioid' category. For this study 'tapentadol-related' cases will be identified and
19 coded by reviewing all cases from June 2013 (aligned with tapentadol availability as a subsidised
20 medicine in Australia), until September 2018. This is identical to the coding process used with other
21 opioids, the only difference being that the cases will be coded retrospectively from 'other opioids' to
22 'tapentadol' where there is evidence of tapentadol involvement in the ePCR.
23
24
25
26
27
28
29

30 Aim 1 – supply-adjusted trends 2013-2018

31
32 Analysis of supply-adjusted trends will occur by quarterly aggregation of attendances in Victoria, by
33 opioid group, with further aggregation to half-yearly if required to preserve cell sizes of at least five in
34 the majority of cells. Where cell sizes of <5 occur, to preserve anonymity we will report average of all
35 cells with 1-4 cases, rather than the number of cases in that cell. Units will be attendances per 100
36 000mg OME (24).
37
38
39
40

41 *Aim 1 analysis plan*

42
43 Prescription opioid-related ambulance attendances will be aggregated into 3 monthly periods
44 corresponding to yearly quarters. Basic descriptive statistical analyses will be used to explore these
45 attendances in Victoria, analyses include frequencies (number of attendances), proportions
46 (demographics), and supply-adjusted rates.
47
48
49

50
51 Poisson regression will be used to assess trends in supply-adjusted rates for Victoria. Regression
52 models will be fitted (one for each opioid), and adjusted for quarterly and yearly trends with the
53 number of days per month used to offset the regression. Rates will be calculated for Victoria (where
54 completed data are available), and compared with rates observed in other states for the time periods
55 that data are available (Table 1). Due to industrial action, September 2014 contains partially complete
56 data (26 out of 30 days). Supply data for this month will be weighted to represent the average supply
57
58
59
60

1
2
3 for the proportion of days provided for September, with the offset variable representing the total
4 number of days where data has been supplied.
5
6
7

8 The intention is to assess trends within each opioid where the opioid has been solely indicated, as well
9 as a 'multiple opioid' category representing cases where multiple opioids have been indicated.

10
11 However, where this is not possible due to small case numbers, trends will be assessed using all cases
12 in which the opioid has been indicated (sole use and multiple opioids).
13
14
15

16 Aim 2 – characteristics of attendances

17 For this analysis, opioid-related attendances will be analysed by opioid type listed above, by
18 characteristics as per Table 2 (additional details on variables are contained in Appendix B).
19
20
21

22 *Aim 2 analysis plan*

23
24 Multinomial logistic regression will be used to analyse characteristics of opioid-related attendances by
25 opioid type. Opioid type (sole use of each opioid and multiple opioid use) will be used as the
26 dependant variable, with each category being compared to morphine as mid-potency opioid, regressed
27 on each characteristic separately. If the number of morphine cases is insufficient to allow use as a
28 reference category then oxycodone will become the reference category. Each model will be adjusted
29 for using a collapsed state variable (where jurisdictions with expected fewer cases such as the
30 Australian Capital Territory and Northern Territory will be aggregated into an 'other states' category).
31 When considering GCS as a proxy for severity, the model will be further adjusted for age, gender,
32 concurrent alcohol use, concurrent illicit drug use (excluding heroin), concurrent heroin use, and
33 concurrent non-opioid pharmaceutical use. All other models will be further adjusted for age, gender
34 and other substance use (as an aggregated variable of concurrent alcohol use, illicit drug use, heroin,
35 and non-opioid pharmaceutical misuse). Results will be reported as odds ratios. Comparison between
36 states will be analysed through an interaction between state and characteristic.
37
38
39
40
41
42
43
44
45
46
47

48 Aim 3 – qualitative analysis of contexts of oxycodone and tapentadol-related attendances

49 Detail from the free-text fields from the ePCR will be utilised to establish a more complete picture of
50 the ambulance attendance. These data are subject to rigorous coding by a highly trained team of
51 coders using well-established and tested coding frameworks for existing fields, however additional
52 uncoded data are available in these free-text fields are rarely used for qualitative analyses. Some
53 studies have used text-based information to explore specific phenomena in further detail, such as
54 intentional and unintentional injury (28) and heroin overdose (29).
55
56
57
58
59
60

1
2
3 We will use text-based case descriptions of oxycodone-related and tapentadol-related cases. These
4 will be qualitatively examined in order to provide insight into the situationally-specific contexts of the
5 ambulance attendances outside of the characteristics captured in routinely coded variables. We will
6 compare tapentadol-related cases (with tapentadol being a newer ‘atypical’ opioid with a suggested
7 lower rate of associated adverse events (8) and less non-medical use (30)), to oxycodone-related
8 attendances, as oxycodone is the predominant opioid-analgesic prescribed in Australia (31) and has a
9 well-recognised abuse liability (11). We will consider the details of circumstances surrounding the
10 presentation including details provided on the role and effect of the opioid used.
11
12
13
14
15
16

17 *Aim 3 analysis plan*

18 Qualitative coding will occur in two stages. First, an initial group of randomly selected cases
19 (estimated n=30-40 until saturation has occurred) will be examined by two researchers to
20 independently determine a coding framework. The researchers will negotiate a consensus framework,
21 then code the remaining cases using this agreed upon framework. The project team will convene
22 regularly to discuss coding techniques as they develop as well as emerging themes. A 10% sample of
23 cases will be checked by a third researcher to confirm coding consistency, with further cases reviewed
24 if inconsistencies are identified.
25
26
27
28
29
30

31 We will examine an equal number of tapentadol- and oxycodone-related cases, based on the number
32 of cases identified for tapentadol (the less frequently used opioid). We will use a random number
33 generator via Excel to randomly select an equal size number of oxycodone-related cases for
34 qualitative comparison (i.e. the same number of cases as in the tapentadol-related case group), and
35 perform the same analyses for oxycodone-related presentations. To ensure that selected oxycodone
36 cases represent all oxycodone cases the sub-group of oxycodone-related attendances will be selected
37 by weighted random sampling, with weightings on the basis of sex, age group, jurisdiction and if the
38 attendance was related to self-harm. Cases involving both tapentadol and oxycodone will be
39 considered as a separate group.
40
41
42
43
44
45

46 In addition to qualitative analysis, multinomial regression will be used to analyse coded variables
47 representing different aspects of attendance context surrounding three mutually exclusive groups: (1)
48 tapentadol-related cases, (2) oxycodone-related cases, and (3) cases that are related to the concomitant
49 use of tapentadol and oxycodone (i.e. considered-related to both opioids). Results will be reported as
50 odds ratios.
51
52
53
54

55 All quantitative analysis for aims 1-3 will be conducted in STATA (StataCorp. 2013. Stata Statistical
56 Software: Release 13. College Station, TX: StataCorp LP), with p values less than 0.05 considered
57
58
59
60

1
2
3 significant. Qualitative data will be managed and analysed using nVivo 12.0 (32), but any subsequent
4 quantitative analyses conducted using STATA as above.
5
6
7

8 Handling known or expected missing data 9

10 Where there are missing data for the characteristics of attendances, we will report the available
11 sample size for each variable. To enable calculation of rates for each quarter with potentially
12 identifiable cases (cell size 1-4), we will impute a value representing the mean for all potentially
13 identifiable cases. This will preserve the total number of cases without compromising privacy of
14 individuals. This will preserve the total number of cases without compromising privacy of
15 individuals.
16
17
18

19 There are three months of missing Victorian data due to industrial action (October – December 2014)
20 with partial missing data (4 days) for September 2014. For these months, to enable calculation of rates
21 (Aim 1), we will impute values based on data from September – December in the previous and
22 following year (2013 and 2015). In a planned sensitivity analysis, we will compare results using
23 imputed data to results excluding missing data and report any differences observed.
24
25
26
27
28

29 Ethics and dissemination 30

31 Ethics approval related to analysis of ambulance attendance data was obtained from the Eastern
32 Health Human Research Ethics Committee (E122 08-09), with an amendment specific to the
33 qualitative analysis. Consistent with the ethics approval, cells of <5 will not be reported, though
34 zeroes will be preserved. Due to the sensitivity and potentially identifiable nature of the data line item
35 data is not available for sharing, consistent with the ethics approval.
36
37
38
39

40 We will present project findings at relevant scientific conferences. We plan to submit findings for
41 publication as two peer-reviewed journal articles. One article will incorporate the quantitative analysis
42 (aim 1 and 2) and one paper report the qualitative analysis (aim 3). We will report findings in
43 accordance with the REporting of studies Conducted using Observational Routinely-collected health
44 Data (RECORD) statement, an extension of the STROBE statement for reporting items specific to
45 observational studies using routinely collected health data (33).
46
47
48
49
50

51 Patient and public involvement 52

53 Interpretation of the findings and dissemination will be informed by people with lived
54 experience through contact with consumer organisations such as the Association of
55 Participating Service Users.
56
57
58
59
60

Discussion

Strengths and limitations

Recommendations for methods for pharmacovigilance studies identified a number of important features, depending on the aims of the study and the methods employed (16). These include the prospective publication of a study protocol including a detailed statistical analysis plan, transparency around study funding and publication in open-access journals. This study will conform to these requirements.

This study has several strengths. Firstly, coded ambulance data captures a broader range of outcomes and a wider population of people with extramedical pharmaceutical opioid use than may be captured in abuse liability studies, clinical trials, or spontaneous AE reporting systems.

Secondly, this study's population level database accurately codes detailed information about each attendance. This level of detail can provide important insights into harms related to substance use (17-19, 34-36). This study will represent an extension of these studies to provide a detailed analysis of rates and characteristics of harms related with widely used pharmaceutical opioids, and is strengthened by the use of population level supply data to calculate supply-adjusted rates. Finally, the study will be first to provide detailed context around circumstances of pharmaceutical opioid related ambulance attendances, utilising coding of qualitative data.

There are limitations in the use of data collected for operational purposes, similar to with hospital inpatient and emergency department data. There is potential for biases to exist in collection and coding, and incomplete or inconsistent recording of variables. Substance involvement is determined from patient-provided information, others at the scene, or paramedic's clinical assessment, not from toxicological testing. Other clinical details (e.g. mental health symptoms) are also determined in this way.

Rates of ambulance attendances are calculated based on sales data. Due to frequent ordering and limited capacity for controlled drug storage at the community pharmacy level, sales closely approximate supply. Use of sales data addresses limitations with publicly funded prescription data, which omits privately purchased prescriptions and over-the-counter medications and therefore is an incomplete measure of community opioid supply. Finally, as this is a naturalistic study, we cannot know if different patient populations are more likely to receive a given opioid. As such, there may be

1
2
3 unmeasured confounders. Randomised trials can address this limitation; however, patients who use
4 opioids extramedically are usually excluded from trials.
5
6
7

8 Data statement

9
10
11 To protect privacy and confidentiality, data from the Ambo Project are provided to Turning Point
12 under strict conditions for the storage, retention and use of the data. The current approval permits
13 storage of the data at one site, Turning Point, with any analysis to be undertaken onsite, no data to be
14 removed, and no dissemination of unit level data. Researchers wishing to undertake additional
15 analyses of the data are invited to contact Turning Point as the data custodians.
16
17
18

19 Conclusion

20
21
22 This will be the first detailed study to compare coded ambulance ePCR as a population level indicator
23 of prescription opioid-related harm. These data will complement ongoing studies examining
24 extramedical use of tapentadol in sentinel populations of people who use drugs, and data from poisons
25 information centres (37). The data in this study represent all acute presentations in community settings
26 where extramedical use of a pharmaceutical opioid analgesic is considered related to the ambulance
27 attendance. This unique dataset has national reach and demonstrated consistency and completeness
28 over multiple years. It will provide one of the most complete analyses of relative harms due to
29 extramedical use for a range of pharmaceutical opioids to date. The study will add to our knowledge,
30 and lead to a more nuanced understanding of whether different pharmaceutical opioids are associated
31 with different harms.
32
33
34
35
36
37
38
39

40 Acknowledgements

41 We acknowledge Sharon Matthews and the population health team of coders who code the data, and
42 the ambulance services around Australia who provide the data.
43
44
45

46 Author statement

47
48 Suzanne Nielsen (SN) initially conceptualised the study and drafted the initial design, with input from
49 Rose Crossin (RC), Debbie Scott (DS) and James Wilson (JW). Cathy Martin (CM) and Melissa
50 Middleton (MM) provided input on, and drafted the statistical analysis plan. SN, RC, DS, JW, Tina
51 Lam (TL), Karen Smith (KS) and Dan Lubman (DL) contributed the drafting of the protocol
52 manuscript and revisions of the protocol. KS, DL and DS lead the broader Victorian Ambo Project
53 and the National Ambo project from which the data is drawn and provided detailed technical advice
54 relating to procedures from that study to inform the development of this study and analysis of the
55 data.
56
57
58
59
60

References:

1. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2018;18(6):1556-68.
2. Krishnamurti C, Rao SC. The isolation of morphine by Serturmer. *Indian journal of anaesthesia*. 2016;60(11):861-2.
3. Pasternak GW, Pan Y-X. Mu opioids and their receptors: evolution of a concept. *Pharmacological reviews*. 2013;65(4):1257-317.
4. Pergolizzi JV, LeQuang JA, Taylor R, Ossipov MH, Colucci D, Raffa RB. Designing safer analgesics: a focus on μ -opioid receptor pathways. *Expert Opinion on Drug Discovery*. 2018;13(10):965-72.
5. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in Tramadol: Pharmacology, Metabolism, and Misuse. *Anesthesia and analgesia*. 2017;124(1):44-51.
6. Bravo L, Mico JA, Berrocoso E. Discovery and development of tramadol for the treatment of pain. *Expert Opinion on Drug Discovery*. 2017;12(12):1281-91.
7. Vadivelu N, Timchenko A, Huang Y, Sinatra R. Tapentadol extended-release for treatment of chronic pain: a review. *Journal of pain research*. 2011;4:211-8.
8. Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics. *Drug Saf*. 2018;41(8):787-95.
9. Babalonis S, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL. Abuse liability and reinforcing efficacy of oral tramadol in humans. *Drug and alcohol dependence*. 2013;129(1-2):116-24.
10. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2008;33(5):1179-91.
11. Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. *Journal of medical toxicology : official journal of the American College of Medical Toxicology*. 2012;8(4):335-40.
12. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the united states: A retrospective analysis of the past 50 years. *JAMA psychiatry*. 2014;71(7):821-6.
13. Turk DC, O'Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, et al. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. *Pain*. 2012;153(10):1997-2008.
14. Peacock AG, D., Sutherland, R., Uporova, J., Karlsson, A., Bruno, R., Dietze, P., Lenton, S., Alati, R., Degenhardt, L., & Farrell, M. Australian Drug Trends 2018. Key findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney. National Drug and Alcohol Research Centre, UNSW Australia; 2018.
15. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®). *Pain Medicine*. 2007;8(2):157-70.
16. Peacock A, Larance B, Bruno R, Pearson SA, Buckley NA, Farrell M, et al. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. *Addiction*. 2019, 114(3):389-399

17. Nielsen S, Dietze P, Lee N, Cantwell K, Taylor D. Methadone and Buprenorphine related ambulance attendances: A population-based indicator of adverse events. *Journal of Substance Abuse Treatment*. 2008;35(4):457-61.
18. Heilbronn C, Lloyd B, McElwee P, Eade A, Lubman DI. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. *Drug Alcohol Rev*. 2013;32(4):405-11.
19. Crossin R, Scott, D., Arunogiri, S., Smith, K., Dietze, P. M., & Lubman, D. I. Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. *Medical Journal of Australia*. 2019. 210(2):75-79
20. Editors Plos Medicine. Observational studies: getting clear about transparency. *PLoS Medicine*. 2014;11(8):e1001711-e.
21. West R. Trial protocols. *Addiction*. 2012;107(9):1544-.
22. Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. *Addiction*. 2015;110(2):226-37.
23. Australian Bureau of Statistics. 3101.0 - Australian Demographic Statistics, Mar 2018. Accessed from: <http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0>. 2018.
24. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. *Pharmacoepidemiology and Drug Safety*. 2016;25(6):733-7.
25. Roxburgh A, Hall WD, Dobbins T, Gisev N, Burns L, Pearson S, et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. *Drug & Alcohol Dependence*. 2017;179:192-8.
26. Therapeutic Goods Administration. Database of Adverse Event Notifications – medicines. Canberra. 2018. <https://www.tga.gov.au/database-adverse-event-notifications-daen>. Accessed 02 Jan 2019
27. Murff HJ, Patel VL, Hripcsak G, Bates DW. Detecting adverse events for patient safety research: a review of current methodologies. *Journal of Biomedical Informatics*. 2003;36(1):131-43.
28. Backe SN, Andersson R. Monitoring the “tip of the iceberg”: Ambulance records as a source of injury surveillance. *Scandinavian Journal of Public Health*. 2008;36(3):250-7.
29. Bammer G, Ostini R, Sengoz A. Using ambulance service records to examine nonfatal heroin overdoses. *Australian journal of public health*. 1995;19(3):316-7.
30. Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. *Pain Med*. 2015;16(1):119-30.
31. Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. *Pharmacoepidemiology and Drug Safety*. 2016;25(5):521-38.
32. Bazeley P, Jackson K. *Qualitative Data Analysis with NVivo* (2nd ed.). London: Sage; 2013.
33. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Medicine*. 2015;12(10):e1001885-e.
34. Lloyd BK, McElwee PR. Trends over time in characteristics of pharmaceutical drug-related ambulance attendances in Melbourne. *Drug and Alcohol Review*. 2011;30(3):271-80.
35. Dietze P, Jolley D, Cvetkovski S, Cantwell K, Jacobs I, Indig D. Characteristics of non-fatal opioid overdoses attended by ambulance services in Australia. *Aust N Z J Public Health*. 2004;28(6):569-75.

- 1
2
3 36. Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-
4 hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. *Med J Aust.*
5 2008;188(12):709-11.
6
7 37. Peacock A, Larance B, Farrell M, Cairns R, Buckley N, Degenhardt L. Opioid use
8 and harms associated with a sustained-release tapentadol formulation: a postmarketing study
9 protocol. *BMJ Open.* 2018;8(3):e020006.
10
11 38. Campbell G, Nielsen S, Bruno R, Lintzeris N, Cohen M, Hall W, et al. The Pain and
12 Opioids IN Treatment (POINT) study: Characteristics of a cohort using opioids to manage
13 chronic non-cancer pain. *Pain.* 2015;156(2):231-42.
14
15 39. Rhodes AE, Bethell J, Spence J, Links PS, Streiner DL, Jaakkimainen RL. Age-sex
16 differences in medicinal self-poisonings: a population-based study of deliberate intent and
17 medical severity. *Social psychiatry and psychiatric epidemiology.* 2008;43(8):642-52.
18
19 40. Gunnell D, Ho D, Murray V. Medical management of deliberate drug overdose: a
20 neglected area for suicide prevention? *Emergency medicine journal : EMJ.* 2004;21(1):35-8.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Summary of data availability across jurisdictions

State / Territory	Notes on data available [^]
ACT	All cases coded one month per quarter from March 2015 until December 2017
NSW	All cases coded one month per quarter from March 2015 until December 2017
NT	All cases coded one month per quarter from March 2016 until December 2017
QLD	All cases coded one month per quarter from March 2015 until December 2016
TAS	All cases coded one month per quarter from March 2014, until December 2017
VIC	All cases coded from January 2012 till September 2018
WA & SA	Data not yet available

[^] We will conduct a comparison on supply-adjusted rates of attendance for Victoria and other states utilising periods of time where corresponding data are available.

For peer review only


Table 2. Variables and response options to be examined in association with pharmaceutical opioid-related ambulance attendances

Variable	Response options
Presenting Glasgow Coma Scale (GCS)	3 (non-responsive), 4-12 (moderate-severe impairment), 13-15 (minor-no impairment)
Presenting respiratory rate (breaths per minute)	<6, 6-12, >12
Transport to hospital	Not transported, transported
Naloxone administered: not stated, yes	Not stated, yes
Naloxone response: not effective, effective	Not effective, effective
Sex of patient	Male, female, other/unspecified
Age of patient	12-34, 35-54, 55-65 (nearing retirement age) and 65+^
Socio-economic status based on residential postcode	Quintile 1-5 based on SEIFA-IRSD 201s, IRSD 2016 (30)
Concurrent alcohol involvement	Not stated, alcohol involved but no evidence of intoxication, alcohol intoxication [∞]
Concurrent heroin involvement	Not stated, present
Concurrent illicit drug use (excluding heroin)	based on the presence of at least one of the illicit drugs coded for; meth(amphetamine), cannabis, synthetic cannabinoids, emerging psychoactive substances, cocaine, MDMA, GHB, ketamine, LSD, psilocybin, inhalant, illicit drug other or unspecified)
Concurrent non-opioid extramedical pharmaceutical use	not stated, present (based on the presence of at least one of the pharmaceutical groups coded for; non-opioid analgesics, benzodiazepines, anti-depressants, anti-psychotics, anti-convulsants, opioid-dependence treatments, pharmaceutical stimulants, other medication)
Co-morbid mental health symptoms	not stated, present (based on the presence of at least one of; symptoms of anxiety, depression, psychosis, social / emotional distress, symptoms associated with disorders with clinical evidence, and mental health unspecified)
Co-morbid suicidal thoughts or behaviours	Not stated, present (based on the presence of at least one of; suicidal ideation, suicide attempt)
Co-morbid non-suicidal self-injury	Not stated, present (based on the presence of at least one of; threat of non-suicidal self-injury, non-suicidal self-is, non-suicidal self-injury)
Accidental overdose	Not stated, yes
Unknown intent overdose#	Not stated, yes
Past history of psychiatric issues	Not stated, present (based on the presence of at least one of; past history of mood disorder, psychosis, suicidal ideation, suicide attempt, alcohol and other drug misuse)
<p>^based on previous age categories used in studies of opioid use for pain (38). We will exclude cases where age is reported to be less than 12 due to the unclear intention of use in children of this age, consistent with previous research (39, 40).</p> <p>#(where information provided in the patient care records by the paramedic means that the coding team cannot determine if the overdose was accidental or if there was suicidal intent)</p> <p>∞The involvement of alcohol is coded as 'alcohol involved' and 'alcohol intoxication'. Attendances where the person has consumed alcohol, but the paramedic notes do not clearly indicate alcohol intoxication are coded as 'alcohol involved' and 'alcohol intoxication is a subset of 'alcohol involved'. The default code is for 'alcohol involved' unless the paramedic notes provide clear evidence of alcohol intoxication.</p>	

1
2
3 Figure Captions:
4

5 Figure 1- Overview of study processes and data sources (VIC = Victoria, NSW = New South Wales,
6 QLD = Queensland, TAS = Tasmania, ACT = Australian Capital Territory, NT = Northern Territory)
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Supplementary materials

Appendix A. Description of coder training and inter-rated reliability processes	2
Appendix B. Description of variables to be examined in association with pharmaceutical opioid-related ambulance attendances	3
References	9

For peer review only

Appendix A. Description of coder training and inter-rated reliability processes

Research Assistants undertake extensive and ongoing training to ensure coding is consistent. To assist with this, coding guides are utilised that detail categories, the process of classification, provide examples of typical attendance types, and examples of uncommon attendance types. When a new Research Assistant commences, they are first trained by senior researchers, and then paired with multiple experienced Research Assistants on a rotating basis, until they and their senior coding partner are confident of coding consistency. Senior researchers review attendances coded by new Research Assistants to ensure inter- and intra-coder reliability. In addition to training upon appointment, all Research Assistants participate in monthly ongoing training. This training covers issues like complex cases or the introduction of new variables. This training is completed with workshops and “dummy case exercises”.

On a day-to-day basis, if Research Assistants are not confident in coding a specific attendance, the attendance is escalated to a senior researcher for review (<1% of attendances). These review cases then feed into regular workshops, which are also used to identify common coding issues, and disseminate coding clarifications on an ongoing basis.

To maintain inter-coder validation, inter-rater review audits are completed by a senior researcher. These are used as a personal learning tool for Research Assistants, and to identify common issues that may need to be addressed across the coding team. As an example of inter-coder validation, results of the most recent coding audit are described below: A maximum of 90 previously coded attendances per Research Assistant were extracted, from the Victoria Quarter 1, 2017 dataset. The 90 attendances met 26 criteria for case-classification. Each Research Assistant then re-coded a random selection of attendances for which they were not the original coder. At that time, there were 23 individual Research Assistants, and the attendances they re-coded came from an average of 9 ± 3 (mean \pm standard deviation) other Research Assistants. A total of 1,718 attendances were re-coded, which meant 221,622 AOD variables were re-coded, of which only 470 differences were identified (i.e. 0.2% of variables). Differences were systematically identified, and reviewed by a senior researcher for personalised feedback to each Research Assistant and then followed up with systemic team training.

Appendix B. Description of variables to be examined in association with pharmaceutical opioid-related ambulance attendances

Variable	Description	Transformations/ intended aggregations and final response options used for analyses	Data source
Presenting Glasgow Coma Scale (GCS)	The Glasgow Coma Scale [1] is a 13 point (range 3-15) scale that assesses injured patients' level of consciousness. The GCS's overall reliability is adequate [2], and it is used by prehospital and hospital staff in most English speaking countries and most of Europe [3].	Response Options: 3 (non-responsive), 4-8 (severe impairment), 9-12 (moderate impairment), 13-15 (minor-no impairment), consistent with previous research with substance-related attendances [4, 5]. This study further isolated the "non-responsive" group (GCS=3) who would not have responded at all, to any of the three components of eye, verbal and motor response to external stimuli.	GCS score is assessed and directly entered into the ePCR by trained paramedics.
Presenting respiratory rate (breaths per minute)	There are not clearly defined standard grouping for respiration rate. However, the normal adult respiration rate is generally considered 12-20 breaths per minute [6], and high doses of opioids depress ventilation [7]. The dispatch protocols from the ambulance systems involved in this study class less than 6 breaths a minute as ineffective breathing.	Grouped into three response Options: <6, 6-12, >12	Respiration rate is assessed and directly entered into the ePCR by trained paramedics.
Transport to hospital	Transport outcome relating to attendance	Response Options: Not transported, transported	Outcome of attendance directly entered into the ePCR as a binary variable by trained paramedics and validated by trained coders after reviewing free-text fields.
Naloxone administered: not stated, yes	Naloxone is an opioid antagonist that reverses the effects of opioid overdose [7].	Response Options: Not stated, yes	Binary variable in ePCR, entered by trained paramedic and validated by trained coders after free-text fields.

Naloxone response: not effective, effective		Response Options: Not effective, effective	Binary variable entered by trained paramedic and validated by coders checking free text field on clinical descriptions e.g. GCS ~3 returning to GCS ~15.
Sex of patient	Sex is coded into male, female and non-binary options, however states vary on how they to record non-binary gender. Codiers validate and re-code gender as male, female, and other/unknown.	For these analyses response options were coded as: Male (0), female (1), other/unknown (9), missing (.) All patients regardless of sex included in analyses related to Aim 1 (rates) and Aim 3 (context of presentation). Those with known sex will be included in the analyses for Aim 2, with missing data quantified.	Four options in the ePCR entered by paramedics, missing data may be coded based on information in free-text.
Age of patient	Our categories were based on previous age categories used in studies of opioid use for pain which were <55, 55-65 and 65+ [8] to enable comparison. In Australia, most overdoses occur in adults with the peak age category in 35-44 [9] and increases observed in older age categories. For this reason we have split those aged from 12 -54 into two categories, 12-34 and 35-55, to enable comparison with national overdose trends. Smaller age groups are not possible due to low rates in younger adults leading to potential censoring of cells. We will exclude cases where age is reported to be less than 12 due to the unclear intention of use in children of this age, consistent with previous research [10, 11].	Response Options: 12-34, 35-54, 55-65 (nearing retirement age) and 65+	DOB is entered by paramedic, missing data may be coded based on information in free-text.

<p>Socio-economic status based on residential postcode</p>	<p>The Socio-Economic Indexes for Areas (SEIFA) ranks geographic areas according to relative socio-economic advantage and disadvantage [12, 13]. The SEIFA is one of the most commonly used measures for socioeconomic status in Australia, and it has been updated every 10 years with Census data since 1986 [14].</p> <p>Lower scores indicate more disadvantaged areas and higher scores indicate more advantaged areas.</p>	<p>Response Options: Quintile 1-5.</p> <p>At Turning Point, the postcode from the ePCR is linked to the Australian Bureau of Statistics' (ABS) database of SEIFA ranks by postcode (2016), and then these ranks were aggregated into quintiles specific to each state.</p>	<p>Postcode is entered by paramedic</p>
<p>Concurrent alcohol involvement</p>	<p>Concurrent alcohol use is captured because the simultaneous use of multiple depressant drugs (e.g. opioids, alcohol and heroin) increase the risk of overdose [15].</p>	<p>Response Options: Not stated, alcohol involved but no evidence of intoxication, alcohol intoxication.</p> <p>The involvement of alcohol is coded as 'alcohol involved' and 'alcohol intoxication'. Attendances where the person has consumed alcohol, but the paramedic notes do not clearly indicate alcohol intoxication are coded as 'alcohol involved', and 'alcohol intoxication' is a subset of 'alcohol involved'. The default code is for 'alcohol involved' unless the paramedic notes provide clear evidence of alcohol intoxication. For this study, these cases were recoded into exclusive categories – not stated, alcohol involved but no evidence of intoxication and alcohol intoxication.</p>	<p>Coders extract information about alcohol involvement from free-text fields as 'not stated' or 'alcohol involved'. There is a subcategory of 'intoxication' under 'alcohol involved'.</p>

Concurrent heroin involvement	Response Options: Not stated, present	Analysed as binary coded variable.	Coders extract information about heroin involvement from free-text fields and code.
Concurrent illicit drug use (excluding heroin)	Response Options: Not stated, present (based on the presence of at least one of the illicit drugs coded for; meth(amphetamine), cannabis, synthetic cannabinoids, emerging psychoactive substances, cocaine, MDMA, GHB, ketamine, LSD, psilocybin, inhalant, illicit drug other or unspecified)	Not stated/ present if any one of the illicit substances listed are reported as being used in the ePCR	Coders extract information about illicit drug involvement from free-text fields and code.
Concurrent non-opioid extramedical pharmaceutical use	Response Options: Not stated, extramedical use present (based on the presence of at least one of the pharmaceutical groups coded for; non-opioid analgesics, benzodiazepines, anti-depressants, anti-psychotics, anti-convulsants, opioid-dependence treatments, pharmaceutical stimulants, other medication)	Not stated/ present if any one of the pharmaceutical drugs listed are reported in the ePCR	Coders extract information about extramedical use of pharmaceutical drugs from free-text fields and code.
Co-morbid mental health symptoms	Response Options: Not stated, present (based on the presence of at least one of; symptoms of anxiety, depression, psychosis, social / emotional distress, symptoms associated with disorders with clinical evidence, and mental health unspecified). Symptomology is reported rather than diagnoses, as paramedics do not diagnose mental illness.	Recorded as binary option of not stated/ present if any one co-morbid symptoms listed are reported in the ePCR	Coders extract information from free-text fields and code.
Co-morbid suicidal thoughts or behaviours	Response Options: Not stated, present (based on the presence of at least one of; suicidal ideation, suicide, suicide attempt)	Recorded as binary option of not stated/ present if any one co-morbid suicidal thoughts or behaviours listed are reported in the ePCR	Coders extract information from free-text fields and code.
Co-morbid non-suicidal self-injury	Response Options: Not stated, present (based on the presence of at least one of;	Recorded as binary variable of not stated or present based on either threat of non-suicidal	Coders extract information from free-text fields and code.

	threat of non-suicidal self-injury, non-suicidal self-injury)	self-injury or non-suicidal self-injury documented in the ePCR	
Unintentional alcohol and other drug overdose	Where information provided in the patient care records by the paramedic suggests that the person did not intend to die (though they may have intended to take the substance). Overdose (also referred to as <i>AOD poisoning</i>) determined using GCS < 9 or 10x dose (for pharmaceuticals), however must also be evidence available to suggest poisoning was unintentional to be coded as yes.	Recorded as binary variable of not stated, yes	Coders extract information from free-text fields and code.
Undetermined intent overdose	Where information provided in the patient care records by the paramedic means that the coding team cannot determine if the overdose was unintentional (also referred to as ' <i>accidental</i> ') or if there was suicidal intent.	Response Options: Not stated, yes	Coders extract information from free-text fields and code.
Past history of psychiatric issues	Response Options: Not stated, present (based on the presence of at least one of; past history of mood disorder (including anxiety, depression, PTSD, Bipolar and OCD), psychosis, suicidal ideation, suicide attempt, alcohol and other drug misuse).	Response Options: Not stated, present	Coders extract information from free-text fields and code.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

1. Teasdale, G. and B. Jennett, *Assessment of coma and impaired consciousness: A Practical Scale*. The Lancet, 1974. **304**(7872): p. 81-84.
2. Reith, F., et al., *The reliability of the Glasgow Coma Scale: a systematic review*. Intensive Care Medicine, 2016. **42**(1): p. 3-15.
3. Barlow, P., *A practical review of the Glasgow Coma Scale and Score*. The Surgeon, 2012. **10**(2): p. 114-119.
4. Dietze, P.M., et al., *Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria*. Med J Aust, 2008. **188**(12): p. 709-11.
5. Nielsen, S., et al., *Methadone and Buprenorphine related ambulance attendances: A population-based indicator of adverse events*. Journal of Substance Abuse Treatment, 2008. **35**(4): p. 457-461.
6. Flenady, T., T. Dwyer, and J. Applegarth, *Accurate respiratory rates count: So should you!* Australas Emerg Nurs J, 2017. **20**(1): p. 45-47.
7. Merlin, M.A., et al., *Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses*. The American Journal of Emergency Medicine, 2010. **28**(3): p. 296-303.
8. Campbell, G., et al., *Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain: do different measures identify the same patients?* Pain. **In Press**(Accepted March 1, 2016).
9. Australian Institute for Health and Welfare, *Opioid harm in Australia and comparisons between Australia and Canada*. 2018.
10. Rhodes, A.E., et al., *Age-sex differences in medicinal self-poisonings: a population-based study of deliberate intent and medical severity*. Soc Psychiatry Psychiatr Epidemiol, 2008. **43**(8): p. 642-52.
11. Gunnell, D., D. Ho, and V. Murray, *Medical management of deliberate drug overdose: a neglected area for suicide prevention?* Emergency medicine journal : EMJ, 2004. **21**(1): p. 35-38.
12. Australian Bureau of Statistics, *2033.0.55.001 - Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016*. Canberra. . 2018.
13. Australian Bureau of Statistics. *Socio-Economic Indexes for Areas*. 2018; Available from: <https://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa>.
14. Australian Bureau of Statistics, *Measures of Socioeconomic Status*. 2011.
15. Dietze, P., et al., *When is a little knowledge dangerous?: Circumstances of recent heroin overdose and links to knowledge of overdose risk factors*. Drug and Alcohol Dependence, 2006. **84**(3): p. 223-230.

BMJ Open

Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029170.R2
Article Type:	Protocol
Date Submitted by the Author:	11-Apr-2019
Complete List of Authors:	Nielsen, Suzanne; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre; UNSW Sydney, Crossin, Rose; Eastern Health Middleton, Melissa; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre Martin, Catherine; Monash University Wilson, James; Eastern Health Lam, Tina; Monash University Eastern Clinical Research Unit, Monash Addiction Research Centre Scott, Debbie ; Monash University Eastern Health Clinical School, Turning Point Smith, Karen; Ambulance Victoria, Centre for Research and Evaluation Lubman, D; Monash University, Turning Point
Primary Subject Heading:	Addiction
Secondary Subject Heading:	Public health
Keywords:	pharmaceutical opioids, ambulance attendance, extramedical use, overdose, oxycodone, tapentadol

SCHOLARONE™
Manuscripts

Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Suzanne Nielsen^{1,4}, Rose Crossin^{1,2,3}, Melissa Middleton¹, Catherine Martin⁵, James Wilson^{2,3}, Tina Lam^{1,2}, Debbie Scott^{1,2,3}, Karen Smith^{5,6,7} and Dan Lubman^{1,2,3}

¹ Monash Addiction Research Centre, Monash University, Frankston, VIC 3199

² Eastern Health Clinical School, Monash University, Box Hill, VIC 3128

³ Turning Point, Eastern Health, Richmond, VIC 3121

⁴ National Drug and Alcohol Research Centre, UNSW Sydney, Randwick, NSW 2031

⁵ Department of Epidemiology and Preventative Medicine, Monash University, Melbourne, VIC 3004

⁶ Ambulance Victoria, Doncaster, VIC 3108

⁷ Department of Community Emergency Health and Paramedic Practice, Monash University, Frankston, VIC 3199

Corresponding author:

A/Professor Suzanne Nielsen

Level 3 Building G, McMahons Road, Frankston, VIC 3199

suzanne.nielsen@monash.edu

+61 3 9904 4641

Word count: 3678

Declarations of competing interests

In the past 5 years, SN has been an investigator on untied education grants from Indivior, unrelated to the current work. SN has provided training to health care professionals on identifying and treating codeine dependence for which her institution has received payment from Indivior. DL has received speaking honoraria from the following: Astra Zeneca, Indivior, Janssen-Cilag, Lundbeck, Servier and Shire, and has participated on Advisory Boards for Indivior and Lundbeck.

Funding

The study is funded by an untied educational grant from Seqirus. SN is the recipient of an NHMRC Career Development Fellowship (#1163961). The funders will have no role in the study design, study conduct, analysis or data interpretation. Prior to publication, representatives from Seqirus will have the opportunity to review the manuscript and provide comment on factual inaccuracies, if identified.

Abstract

Introduction and aims: Extramedical use of, and associated harms with pharmaceutical opioids are common. Analysis of coded ambulance clinical records provides a unique opportunity to examine a national population-level indicator of relative harms. This protocol describes an observational study with three aims: (1) To compare supply-adjusted rates of pharmaceutical opioid-related ambulance attendances for, buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone, morphine, pethidine, tramadol and tapentadol; (2) to compare presentation characteristics for these commonly used pharmaceutical opioids; and (3) to describe the context surrounding ambulance presentations related to oxycodone, a widely used opioid with an established abuse liability, and tapentadol, a more recent ‘atypical’ opioid on the Australian market, with fewer studies that have directly examined signals of extramedical use.

Method: Trained coders extract data from clinical records for ambulance presentations relating to extramedical use of commonly used pharmaceutical opioids. This data forms the basis of a large, national database that captures alcohol and drug related harms. Supply adjusted rates of presentations will be examined using Poisson regression and multinomial logistic regression will be used to compare severity and other characteristics of attendances relating to different pharmaceutical opioids. Tapentadol-related and oxycodone-related cases will be qualitatively examined to understand the situationally-specific contexts of the ambulance attendances outside of the characteristics captured in routinely coded variables.

Ethics and dissemination: Ethics approval related to analysis of ambulance attendance data was obtained from the Eastern Health Human Research Ethics Committee (E122 08-09), with an amendment specific to the qualitative analysis. Findings will be submitted for peer review in 2019. The understanding of risk-profiles in real-world settings is of international public health importance. The analysis and publication of findings from this national dataset of clinical records will provide one of the most nuanced analyses to date of relative harms across nine pharmaceutical opioids over a seven-year period.

Keywords: pharmaceutical opioids, ambulance attendance, extramedical use, overdose, oxycodone, tapentadol

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations

- Strengths of this study include use of coded pharmaceutical opioid-related ambulance attendance data as validated population-level indicator of opioid-related harm such as extramedical use and overdose to inform risk profiles in real-world settings
- We will compare the supply-adjusted rates and characteristics of ambulance attendances with commonly used pharmaceutical opioids
- Limitations include the use of administrative data, and a lack of toxicological data to confirm substances taken

For peer review only

Introduction

Recently, the world's attention has focused on the rapidly escalating opioid-related deaths occurring in North America and other high-income countries (1). This has put into sharp focus the need to understand the risk profiles associated with different pharmaceutical opioids.

The number and potency of available pharmaceutical opioids has increased rapidly over the past decades. Morphine, a selective mu-opioid agonist, was isolated more than 200 years ago (2). Following this, analogues such as diamorphine and codeine were developed. Later, semi-synthetic opioids such as oxycodone (a full agonist at the mu-opioid receptor) and buprenorphine (a partial agonist at the mu-opioid receptor (with activity at delta and kappa) (3) were isolated. In addition, newer 'atypical' opioids such as tramadol and tapentadol exert their analgesic effects via opioid and non-opioid mechanisms (4). Tramadol, a lower potency mu opioid receptor agonist with a more potent metabolite, also selectively inhibits noradrenalin and serotonin uptake (5, 6). Tapentadol is another synthetic opioid, structurally similar to tramadol, with mu-opioid receptor agonism and inhibition of noradrenaline reuptake (7).

A United States (US) study of severe adverse events (SAEs) found a positive linear relationship between opioid potency and SAE rate, with the highest rate observed with hydromorphone (8.02 SAEs/100 kg), and the lowest rate with tapentadol (0.27 SAE/100 kg) (8). This suggests that harms related to opioids may not be equal, though replication studies outside the US are needed.

Abuse liability studies also find differences between prescribed opioids. Differences in the strength of reinforcing or subjective effects between tramadol, oxycodone, codeine have been found (9). Subjective effects of oxycodone appeared greater than codeine, though all opioids examined were reinforcing, particularly at higher doses (9). A separate study examined ratings of 'I feel high', and the amount that people were willing to pay for a drug varying by opioid type (10). Defined doses of diamorphine, morphine, and oxycodone had higher ratings than buprenorphine and fentanyl (10). In this study, oxycodone produced robust reinforcing effects, consistent with systematic review of nine studies that oxycodone had a higher abuse liability relative to other opioids (11).

Although abuse liability may vary in controlled laboratory studies, opioid use in real-world settings can vary as a function of cost, availability and other contextual factors (12). For this reason, pharmacovigilance studies are important to monitor for signals of extramedical use in real-world settings. Further, signals of extramedical use may only appear after trials, as those likely to use opioid

1
2
3 extramedically are often excluded from these studies, so data from diverse populations is important
4 (13).
5
6
7

8 Sentinel surveillance aims to assess nonmedical use and harms with opioids such as oxycodone and
9 morphine (14). For newer opioids, or opioids infrequently used by sentinel study populations,
10 population level studies can more completely assess for signals of extramedical use (15). One
11 population level indicator of opioid-related harm is ambulance attendances. These data are recognised
12 as a valuable data source for identifying population level signals of harm (16). In Australia, the
13 clinical records of ambulance attendances related to extramedical use of pharmaceuticals (i.e. use
14 outside a medical context, or in a higher dose than prescribed) are coded by trained research
15 assistants. These data can inform the risk profile with different pharmaceutical opioids (17), and has
16 been used to monitor harms related to quetiapine and pregabalin (18, 19). These data can determine if
17 unintended harms such as extramedical use and overdose are emerging, and provide information on
18 the frequency, severity and context of presentations.
19
20
21
22
23
24
25

26
27 As such, this paper outlines the design of a study that aims to conduct a detailed examination of
28 ambulance attendances related to pharmaceutical opioids, and test the hypothesis that the context and
29 frequency of harms with different opioids will vary by opioid type. We write this protocol to
30 maximize transparency (20, 21). The study is supported by an untied educational grant by Seqirus,
31 who make Palexia® (tapentadol) and Tramal® (tramadol). The funders have no role in the design,
32 conduct, analysis and interpretation of the study and its findings. As has been highlighted by others in
33 the field (22), prospectively publishing study protocols with primary aims and related analysis plans
34 assist in establishing independence around the study design, providing transparency, and ensuring a
35 commitment to publishing study findings regardless of the outcome (21).
36
37
38
39
40
41
42
43
44

45 Methods

46 Study aims

47 This study has three aims:
48

- 49 1) Compare the supply-adjusted rates of ambulance attendances across commonly used
50 pharmaceutical opioids (buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone,
51 morphine, pethidine, tramadol and tapentadol).
52
- 53 2) Compare presentation characteristics for these nine opioids.
54
- 55 3) Describe the context surrounding ambulance presentations related to two opioids: oxycodone,
56 a widely used opioid with an established abuse liability, and tapentadol, a newer opioid with
57 fewer studies describing extramedical use.
58
59
60

We will answer the following research questions:

1. Do the supply-adjusted rates of ambulance presentations differ by opioid potency?
2. Does the severity of presentation (as measured by presenting Glasgow Coma Scale, GCS) or other characteristics vary by opioid type?
3. Are there differences in the context surrounding ambulance presentations related to extramedical use of oxycodone and tapentadol?

Study design and setting

Data come from ambulance attendances in Victoria; a state which comprises approximately 26% of Australia's population (23), supplemented by national ambulance data. The Victorian dataset provides complete coverage across the study period (June 2013 until September 2018, excluding 3 months of missing data October - December 2014, due to industrial action). Coded electronic patient care records (ePCR) provide information on acute harms arising from extramedical pharmaceutical use, thus allowing comparison of attendance characteristics across multiple opioids.

We will examine data from the National Ambo Project from Queensland, New South Wales, Australian Capital Territory, Northern Territory and Tasmania to determine if Victorian trends are comparable to national trends. National data is available in quarterly 'snap-shot months' (Table 1) and are screened and coded using the same procedures and coders as the Victorian data. See Figure 1 for an overview of data sources and study processes. We will aim to complete case identification by March 2019, with analyses planned for March-April 2019.

Pharmaceutical opioid sales data

We will estimate the amount of each opioid supplied using monthly sales data (IQVIA third party access program). The total amount of each opioid will be calculated by jurisdiction in mg, converted into Oral Morphine Equivalents (OME) (24), and used to calculate a supply-adjusted rate of attendances, consistent with previous studies of pharmaceutical opioid related harm that have adjusted for supply using similar methods (8, 25).

Ambulance attendance data

Ambulance data are collected as part of the Ambo Project, a collaboration between Turning Point, Monash University and Ambulance Victoria (AV). Methods for the Ambo Project have been previously described (e.g. (18, 19)) and are outlined below.

1
2
3 Data includes electronic patient care records (ePCR), computer aided dispatch notes, and clinical
4 details associated with the attendance that provide part of the patient care record (e.g. records of
5 respiration rate and GCS). Primary filtering based on over-inclusive keyword searches identifies
6 attendances with involvement of alcohol, other drugs, or mental health symptomology. This filtered
7 dataset is provided to Turning Point where data cleaning, validation, and coding of the ePCR is
8 performed by a specialist team of research assistants. Details on research assistant training, and
9 interrater review processes are contained in Supplementary files (Appendix A). A systematic and
10 validated coding system captures information from the ePCR. The core criterion used in determining
11 the involvement of a substance is: "Is it reasonable to attribute the immediate or recent (not merely
12 chronic) over- or inappropriate (i.e. extramedical) ingestion of the substance or medication as
13 significantly contributing to the reason for the ambulance attendance?", as determined through
14 examination of the clinical notes. As such, this dataset captures information on acute, not chronic,
15 harms.

16
17
18 For this study, ambulance attendances where extramedical pharmaceutical opioid use was identified
19 as a significant contributor to an attendance will be included. This dataset excludes cases of solely
20 therapeutic use. Pharmaceutical opioid-related attendances include those where; a person prescribed
21 opioids consumed medication more often or in higher than recommended amounts; a person
22 consumed opioids not prescribed to them, or if opioids were consumed with a combination of other
23 substances that contributed to the ambulance attendance. The inclusion criteria mean that
24 extramedical opioid use must significantly contribute to the attendance, however other drugs or
25 substances may have also been over- or inappropriately consumed and the extramedical opioid use
26 may not be the primary or only reason for the ambulance attending. These criteria differentiate Ambo
27 Project data from adverse event reporting from the Therapeutic Goods Administration (TGA)
28 Database of Adverse Event (AE) Notifications (26), which captures spontaneous AEs from prescribed
29 medications. Spontaneous AE reporting can effectively identify serious harms with prescribed
30 medicines, though is recognised to miss the vast majority of AEs (27).

31
32
33 Other associated factors such as alcohol and other drug use, mental health symptoms, and self-harm
34 are also coded. All illicit drug use is coded regardless of quantity. Current mental health
35 symptomology is coded rather than mental health diagnosis as paramedics do not screen or assess
36 mental illness diagnoses during an ambulance attendance.

37
38
39 These methods are consistent across other jurisdictions, which collect quarterly data as part of the
40 National Ambo Project, with the exception that ambulance services in Tasmania, Australian Capital
41 Territory, and the Northern Territory provide all data and do not undertake primary filtering.

1
2
3 All substances related to the attendance are coded; including alcohol, illicit & pharmaceutical drugs.
4 For this project, we will examine buprenorphine (as a single ingredient), codeine (codeine as a single
5 ingredient, and in combination with paracetamol, or ibuprofen, or aspirin), fentanyl, morphine,
6 oxycodone, oxycodone-naloxone, pethidine, tapentadol and tramadol. We will exclude opioids used
7 as treatments for opioid dependence (methadone, buprenorphine-naloxone, or buprenorphine and a
8 single ingredient where indicated that it is for treatment of opioid dependence) as these represent a
9 different clinical indication and specific treatment population.
10
11
12
13
14

15
16 Buprenorphine, codeine, fentanyl, oxycodone, oxycodone-naloxone, morphine, pethidine and
17 tramadol are routinely coded in the Ambo project database. Cases involving tapentadol are routinely
18 coded in an 'other opioid' category. For this study 'tapentadol-related' cases will be identified and
19 coded by reviewing all cases from June 2013 (aligned with tapentadol availability as a subsidised
20 medicine in Australia), until September 2018. This is identical to the coding process used with other
21 opioids, the only difference being that the cases will be coded retrospectively from 'other opioids' to
22 'tapentadol' where there is evidence of tapentadol involvement in the ePCR.
23
24
25
26
27
28
29

30 Aim 1 – supply-adjusted trends 2013-2018

31
32 Analysis of supply-adjusted trends will occur by quarterly aggregation of attendances in Victoria, by
33 opioid group, with further aggregation to half-yearly if required to preserve cell sizes of at least five in
34 the majority of cells. Where cell sizes of <5 occur, to preserve anonymity we will report average of all
35 cells with 1-4 cases, rather than the number of cases in that cell. Units will be attendances per 100
36 000mg OME (24).
37
38
39
40

41 *Aim 1 analysis plan*

42
43 Prescription opioid-related ambulance attendances will be aggregated into 3 monthly periods
44 corresponding to yearly quarters. Basic descriptive statistical analyses will be used to explore these
45 attendances in Victoria, analyses include frequencies (number of attendances), proportions
46 (demographics), and supply-adjusted rates.
47
48
49

50
51 Poisson regression will be used to assess trends in supply-adjusted rates for Victoria. Regression
52 models will be fitted (one for each opioid), and adjusted for quarterly and yearly trends with the
53 number of days per month used to offset the regression. Rates will be calculated for Victoria (where
54 completed data are available), and compared with rates observed in other states for the time periods
55 that data are available (Table 1). Due to industrial action, September 2014 contains partially complete
56 data (26 out of 30 days). Supply data for this month will be weighted to represent the average supply
57
58
59
60

1
2
3 for the proportion of days provided for September, with the offset variable representing the total
4 number of days where data has been supplied.
5
6
7

8 The intention is to assess trends within each opioid where the opioid has been solely indicated, as well
9 as a ‘multiple opioid’ category representing cases where multiple opioids have been indicated.

10
11 However, where this is not possible due to small case numbers, trends will be assessed using all cases
12 in which the opioid has been indicated (sole use and multiple opioids).
13
14
15

16 Aim 2 – characteristics of attendances

17 For this analysis, opioid-related attendances will be analysed by opioid type listed above, by
18 characteristics as per Table 2 (additional details on variables are contained in Appendix B).
19
20
21

22 *Aim 2 analysis plan*

23
24 Multinomial logistic regression will be used to analyse characteristics of opioid-related attendances by
25 opioid type. Opioid type (sole use of each opioid and multiple opioid use) will be used as the
26 dependant variable, with each category being compared to morphine as mid-potency opioid, regressed
27 on each characteristic separately. If the number of morphine cases is insufficient to allow use as a
28 reference category then oxycodone will become the reference category. Each model will be adjusted
29 for using a collapsed state variable (where jurisdictions with expected fewer cases such as the
30 Australian Capital Territory and Northern Territory will be aggregated into an ‘other states’ category).
31 When considering GCS as a proxy for severity, the model will be further adjusted for age, gender,
32 concurrent alcohol use, concurrent illicit drug use (excluding heroin), concurrent heroin use, and
33 concurrent non-opioid pharmaceutical use. All other models will be further adjusted for age, gender
34 and other substance use (as an aggregated variable of concurrent alcohol use, illicit drug use, heroin,
35 and non-opioid pharmaceutical misuse). Results will be reported as odds ratios. Comparison between
36 states will be analysed through an interaction between state and characteristic.
37
38
39
40
41
42
43
44
45
46
47

48 Aim 3 – qualitative analysis of contexts of oxycodone and tapentadol-related attendances

49 Detail from the free-text fields from the ePCR will be utilised to establish a more complete picture of
50 the ambulance attendance. These data are subject to rigorous coding by a highly trained team of
51 coders using well-established and tested coding frameworks for existing fields, however additional
52 uncoded data are available in these free-text fields are rarely used for qualitative analyses. Some
53 studies have used text-based information to explore specific phenomena in further detail, such as
54 intentional and unintentional injury (28) and heroin overdose (29).
55
56
57
58
59
60

1
2
3 We will use text-based case descriptions of oxycodone-related and tapentadol-related cases. These
4 will be qualitatively examined in order to provide insight into the situationally-specific contexts of the
5 ambulance attendances outside of the characteristics captured in routinely coded variables. We will
6 compare tapentadol-related cases (with tapentadol being a newer ‘atypical’ opioid with a suggested
7 lower rate of associated adverse events (8) and less non-medical use (30)), to oxycodone-related
8 attendances, as oxycodone is the predominant opioid-analgesic prescribed in Australia (31) and has a
9 well-recognised abuse liability (11). We will consider the details of circumstances surrounding the
10 presentation including details provided on the role and effect of the opioid used.
11
12
13
14
15

16 17 *Aim 3 analysis plan*

18 Qualitative coding will occur in two stages. First, an initial group of randomly selected cases
19 (estimated n=30-40 until saturation has occurred) will be examined by two researchers to
20 independently determine a coding framework. The researchers will negotiate a consensus framework,
21 then code the remaining cases using this agreed upon framework. The project team will convene
22 regularly to discuss coding techniques as they develop as well as emerging themes. A 10% sample of
23 cases will be checked by a third researcher to confirm coding consistency, with further cases reviewed
24 if inconsistencies are identified.
25
26
27
28
29

30 We will examine an equal number of tapentadol- and oxycodone-related cases, based on the number
31 of cases identified for tapentadol (the less frequently used opioid). We will use a random number
32 generator via Excel to randomly select an equal size number of oxycodone-related cases for
33 qualitative comparison (i.e. the same number of cases as in the tapentadol-related case group), and
34 perform the same analyses for oxycodone-related presentations. To ensure that selected oxycodone
35 cases represent all oxycodone cases the sub-group of oxycodone-related attendances will be selected
36 by weighted random sampling, with weightings on the basis of sex, age group, jurisdiction and if the
37 attendance was related to self-harm. Cases involving both tapentadol and oxycodone will be
38 considered as a separate group.
39
40
41
42
43
44
45

46 In addition to qualitative analysis, multinomial regression will be used to analyse coded variables
47 representing different aspects of attendance context surrounding three mutually exclusive groups: (1)
48 tapentadol-related cases, (2) oxycodone-related cases, and (3) cases that are related to the concomitant
49 use of tapentadol and oxycodone (i.e. considered-related to both opioids). Results will be reported as
50 odds ratios.
51
52
53
54

55 All quantitative analysis for aims 1-3 will be conducted in STATA (StataCorp. 2013. Stata Statistical
56 Software: Release 13. College Station, TX: StataCorp LP), with p values less than 0.05 considered
57
58
59
60

1
2
3 significant. Qualitative data will be managed and analysed using nVivo 12.0 (32), but any subsequent
4 quantitative analyses conducted using STATA as above.
5
6
7

8 Handling known or expected missing data 9

10 Where there are missing data for the characteristics of attendances, we will report the available
11 sample size for each variable. To enable calculation of rates for each quarter with potentially
12 identifiable cases (cell size 1-4), we will impute a value representing the mean for all potentially
13 identifiable cases. This will preserve the total number of cases without compromising privacy of
14 individuals.
15
16
17
18

19 There are three months of missing Victorian data due to industrial action (October – December 2014)
20 with partial missing data (4 days) for September 2014. For these months, to enable calculation of rates
21 (Aim 1), we will impute values based on data from September – December in the previous and
22 following year (2013 and 2015). In a planned sensitivity analysis, we will compare results using
23 imputed data to results excluding missing data and report any differences observed.
24
25
26
27
28

29 Ethics and dissemination 30

31 Ethics approval related to analysis of ambulance attendance data was obtained from the Eastern
32 Health Human Research Ethics Committee (E122 08-09), with an amendment specific to the
33 qualitative analysis. Consistent with the ethics approval, cells of <5 will not be reported, though
34 zeroes will be preserved. Due to the sensitivity and potentially identifiable nature of the data line item
35 data is not available for sharing, consistent with the ethics approval.
36
37
38
39

40 We will present project findings at relevant scientific conferences. We plan to submit findings for
41 publication as two peer-reviewed journal articles. One article will incorporate the quantitative analysis
42 (aim 1 and 2) and one paper report the qualitative analysis (aim 3). We will report findings in
43 accordance with the REporting of studies Conducted using Observational Routinely-collected health
44 Data (RECORD) statement, an extension of the STROBE statement for reporting items specific to
45 observational studies using routinely collected health data (33).
46
47
48
49
50

51 Patient and public involvement 52

53 Interpretation of the findings and dissemination will be informed by people with lived
54 experience through contact with consumer organisations such as the Association of
55 Participating Service Users.
56
57
58
59
60

Discussion

Strengths and limitations

Recommendations for methods for pharmacovigilance studies identified a number of important features, depending on the aims of the study and the methods employed (16). These include the prospective publication of a study protocol including a detailed statistical analysis plan, transparency around study funding and publication in open-access journals. This study will conform to these requirements.

This study has several strengths. Firstly, coded ambulance data captures a broader range of outcomes and a wider population of people with extramedical pharmaceutical opioid use than may be captured in abuse liability studies, clinical trials, or spontaneous AE reporting systems.

Secondly, this study's population level database accurately codes detailed information about each attendance. This level of detail can provide important insights into harms related to substance use (17-19, 34-36). This study will represent an extension of these studies to provide a detailed analysis of rates and characteristics of harms related with widely used pharmaceutical opioids, and is strengthened by the use of population level supply data to calculate supply-adjusted rates. Finally, the study will be first to provide detailed context around circumstances of pharmaceutical opioid related ambulance attendances, utilising coding of qualitative data.

There are limitations in the use of data collected for operational purposes, similar to with hospital inpatient and emergency department data. There is potential for biases to exist in collection and coding, and incomplete or inconsistent recording of variables. Substance involvement is determined from patient-provided information, others at the scene, or paramedic's clinical assessment, not from toxicological testing. Other clinical details (e.g. mental health symptoms) are also determined in this way.

Rates of ambulance attendances are calculated based on sales data. Due to frequent ordering and limited capacity for controlled drug storage at the community pharmacy level, sales closely approximate supply. Use of sales data addresses limitations with publicly funded prescription data, which omits privately purchased prescriptions and over-the-counter medications and therefore is an incomplete measure of community opioid supply. Finally, as this is a naturalistic study, we cannot know if different patient populations are more likely to receive a given opioid. As such, there may be

1
2
3 unmeasured confounders. Randomised trials can address this limitation; however, patients who use
4 opioids extramedically are usually excluded from trials.
5
6
7

8 Data statement

9
10
11 To protect privacy and confidentiality, data from the Ambo Project are provided to Turning Point
12 under strict conditions for the storage, retention and use of the data. The current approval permits
13 storage of the data at one site, Turning Point, with any analysis to be undertaken onsite, no data to be
14 removed, and no dissemination of unit level data. Researchers wishing to undertake additional
15 analyses of the data are invited to contact Turning Point as the data custodians.
16
17
18
19

20 Conclusion

21
22
23 This will be the first detailed study to compare coded ambulance ePCR as a population level indicator
24 of prescription opioid-related harm. These data will complement ongoing studies examining
25 extramedical use of tapentadol in sentinel populations of people who use drugs, and data from poisons
26 information centres (37). The data in this study represent all acute presentations in community settings
27 where extramedical use of a pharmaceutical opioid analgesic is considered related to the ambulance
28 attendance. This unique dataset has national reach and demonstrated consistency and completeness
29 over multiple years. It will provide one of the most complete analyses of relative harms due to
30 extramedical use for a range of pharmaceutical opioids to date. The study will add to our knowledge,
31 and lead to a more nuanced understanding of whether different pharmaceutical opioids are associated
32 with different harms.
33
34
35
36
37
38
39

40 Acknowledgements

41 We acknowledge Sharon Matthews and the population health team of coders who code the data, and
42 the ambulance services around Australia who provide the data.
43
44
45

46 Author statement

47
48 Suzanne Nielsen (SN) initially conceptualised the study and drafted the initial design, with input from
49 Rose Crossin (RC), Debbie Scott (DS) and James Wilson (JW). Cathy Martin (CM) and Melissa
50 Middleton (MM) provided input on, and drafted the statistical analysis plan. SN, RC, DS, JW, Tina
51 Lam (TL), Karen Smith (KS) and Dan Lubman (DL) contributed the drafting of the protocol
52 manuscript and revisions of the protocol. KS, DL and DS lead the broader Victorian Ambo Project
53 and the National Ambo project from which the data is drawn and provided detailed technical advice
54 relating to procedures from that study to inform the development of this study and analysis of the
55 data.
56
57
58
59
60

References:

1. Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2018;18(6):1556-68.
2. Krishnamurti C, Rao SC. The isolation of morphine by Serturmer. *Indian journal of anaesthesia*. 2016;60(11):861-2.
3. Pasternak GW, Pan Y-X. Mu opioids and their receptors: evolution of a concept. *Pharmacological reviews*. 2013;65(4):1257-317.
4. Pergolizzi JV, LeQuang JA, Taylor R, Ossipov MH, Colucci D, Raffa RB. Designing safer analgesics: a focus on μ -opioid receptor pathways. *Expert Opinion on Drug Discovery*. 2018;13(10):965-72.
5. Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in Tramadol: Pharmacology, Metabolism, and Misuse. *Anesthesia and analgesia*. 2017;124(1):44-51.
6. Bravo L, Mico JA, Berrocoso E. Discovery and development of tramadol for the treatment of pain. *Expert Opinion on Drug Discovery*. 2017;12(12):1281-91.
7. Vadivelu N, Timchenko A, Huang Y, Sinatra R. Tapentadol extended-release for treatment of chronic pain: a review. *Journal of pain research*. 2011;4:211-8.
8. Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics. *Drug Saf*. 2018;41(8):787-95.
9. Babalonis S, Lofwall MR, Nuzzo PA, Siegel AJ, Walsh SL. Abuse liability and reinforcing efficacy of oral tramadol in humans. *Drug and alcohol dependence*. 2013;129(1-2):116-24.
10. Comer SD, Sullivan MA, Whittington RA, Vosburg SK, Kowalczyk WJ. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. *Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology*. 2008;33(5):1179-91.
11. Wightman R, Perrone J, Portelli I, Nelson L. Likeability and abuse liability of commonly prescribed opioids. *Journal of medical toxicology : official journal of the American College of Medical Toxicology*. 2012;8(4):335-40.
12. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the united states: A retrospective analysis of the past 50 years. *JAMA psychiatry*. 2014;71(7):821-6.
13. Turk DC, O'Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, et al. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. *Pain*. 2012;153(10):1997-2008.
14. Peacock AG, D., Sutherland, R., Uporova, J., Karlsson, A., Bruno, R., Dietze, P., Lenton, S., Alati, R., Degenhardt, L., & Farrell, M. Australian Drug Trends 2018. Key findings from the National Illicit Drug Reporting System (IDRS) Interviews. Sydney. National Drug and Alcohol Research Centre, UNSW Australia; 2018.
15. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®). *Pain Medicine*. 2007;8(2):157-70.
16. Peacock A, Larance B, Bruno R, Pearson SA, Buckley NA, Farrell M, et al. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. *Addiction*. 2019, 114(3):389-399

17. Nielsen S, Dietze P, Lee N, Cantwell K, Taylor D. Methadone and Buprenorphine related ambulance attendances: A population-based indicator of adverse events. *Journal of Substance Abuse Treatment*. 2008;35(4):457-61.
18. Heilbronn C, Lloyd B, McElwee P, Eade A, Lubman DI. Trends in quetiapine use and non-fatal quetiapine-related ambulance attendances. *Drug Alcohol Rev*. 2013;32(4):405-11.
19. Crossin R, Scott, D., Arunogiri, S., Smith, K., Dietze, P. M., & Lubman, D. I. Pregabalin misuse-related ambulance attendances in Victoria, 2012–2017: characteristics of patients and attendances. *Medical Journal of Australia*. 2019. 210(2):75-79
20. Editors Plos Medicine. Observational studies: getting clear about transparency. *PLoS Medicine*. 2014;11(8):e1001711-e.
21. West R. Trial protocols. *Addiction*. 2012;107(9):1544-.
22. Degenhardt L, Larance B, Bruno R, Lintzeris N, Ali R, Farrell M. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. *Addiction*. 2015;110(2):226-37.
23. Australian Bureau of Statistics. 3101.0 - Australian Demographic Statistics, Mar 2018. Accessed from: <http://www.abs.gov.au/ausstats/abs@.nsf/mf/3101.0>. 2018.
24. Nielsen S, Degenhardt L, Hoban B, Gisev N. A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. *Pharmacoepidemiology and Drug Safety*. 2016;25(6):733-7.
25. Roxburgh A, Hall WD, Dobbins T, Gisev N, Burns L, Pearson S, et al. Trends in heroin and pharmaceutical opioid overdose deaths in Australia. *Drug & Alcohol Dependence*. 2017;179:192-8.
26. Therapeutic Goods Administration. Database of Adverse Event Notifications – medicines. Canberra. 2018. <https://www.tga.gov.au/database-adverse-event-notifications-daen>. Accessed 02 Jan 2019
27. Murff HJ, Patel VL, Hripcsak G, Bates DW. Detecting adverse events for patient safety research: a review of current methodologies. *Journal of Biomedical Informatics*. 2003;36(1):131-43.
28. Backe SN, Andersson R. Monitoring the “tip of the iceberg”: Ambulance records as a source of injury surveillance. *Scandinavian Journal of Public Health*. 2008;36(3):250-7.
29. Bammer G, Ostini R, Sengoz A. Using ambulance service records to examine nonfatal heroin overdoses. *Australian journal of public health*. 1995;19(3):316-7.
30. Butler SF, McNaughton EC, Black RA. Tapentadol abuse potential: a postmarketing evaluation using a sample of individuals evaluated for substance abuse treatment. *Pain Med*. 2015;16(1):119-30.
31. Degenhardt L, Gisev N, Cama E, Nielsen S, Larance B, Bruno R. The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. *Pharmacoepidemiology and Drug Safety*. 2016;25(5):521-38.
32. Bazeley P, Jackson K. *Qualitative Data Analysis with NVivo* (2nd ed.). London: Sage; 2013.
33. Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. *PLoS Medicine*. 2015;12(10):e1001885-e.
34. Lloyd BK, McElwee PR. Trends over time in characteristics of pharmaceutical drug-related ambulance attendances in Melbourne. *Drug and Alcohol Review*. 2011;30(3):271-80.
35. Dietze P, Jolley D, Cvetkovski S, Cantwell K, Jacobs I, Indig D. Characteristics of non-fatal opioid overdoses attended by ambulance services in Australia. *Aust N Z J Public Health*. 2004;28(6):569-75.

- 1
2
3 36. Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-
4 hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. *Med J Aust.*
5 2008;188(12):709-11.
6
7 37. Peacock A, Larance B, Farrell M, Cairns R, Buckley N, Degenhardt L. Opioid use
8 and harms associated with a sustained-release tapentadol formulation: a postmarketing study
9 protocol. *BMJ Open.* 2018;8(3):e020006.
10
11 38. Campbell G, Nielsen S, Bruno R, Lintzeris N, Cohen M, Hall W, et al. The Pain and
12 Opioids IN Treatment (POINT) study: Characteristics of a cohort using opioids to manage
13 chronic non-cancer pain. *Pain.* 2015;156(2):231-42.
14
15 39. Rhodes AE, Bethell J, Spence J, Links PS, Streiner DL, Jaakkimainen RL. Age-sex
16 differences in medicinal self-poisonings: a population-based study of deliberate intent and
17 medical severity. *Social psychiatry and psychiatric epidemiology.* 2008;43(8):642-52.
18
19 40. Gunnell D, Ho D, Murray V. Medical management of deliberate drug overdose: a
20 neglected area for suicide prevention? *Emergency medicine journal : EMJ.* 2004;21(1):35-8.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Summary of data availability across jurisdictions

State / Territory	Notes on data available [^]
ACT	All cases coded one month per quarter from March 2015 until December 2017
NSW	All cases coded one month per quarter from March 2015 until December 2017
NT	All cases coded one month per quarter from March 2016 until December 2017
QLD	All cases coded one month per quarter from March 2015 until December 2016
TAS	All cases coded one month per quarter from March 2014, until December 2017
VIC	All cases coded from January 2012 till September 2018
WA & SA	Data not yet available

[^] We will conduct a comparison on supply-adjusted rates of attendance for Victoria and other states utilising periods of time where corresponding data are available.

For peer review only


Table 2. Variables and response options to be examined in association with pharmaceutical opioid-related ambulance attendances

Variable	Response options
Presenting Glasgow Coma Scale (GCS)	3 (non-responsive), 4-12 (moderate-severe impairment), 13-15 (minor-no impairment)
Presenting respiratory rate (breaths per minute)	<6, 6-12, >12
Transport to hospital	Not transported, transported
Naloxone administered: not stated, yes	Not stated, yes
Naloxone response: not effective, effective	Not effective, effective
Sex of patient	Male, female, other/unspecified
Age of patient	12-34, 35-54, 55-65 (nearing retirement age) and 65+^
Socio-economic status based on residential postcode	Quintile 1-5 based on SEIFA-IRSD 201s, IRSD 2016 (30)
Concurrent alcohol involvement	Not stated, alcohol involved but no evidence of intoxication, alcohol intoxication [∞]
Concurrent heroin involvement	Not stated, present
Concurrent illicit drug use (excluding heroin)	based on the presence of at least one of the illicit drugs coded for; meth(amphetamine), cannabis, synthetic cannabinoids, emerging psychoactive substances, cocaine, MDMA, GHB, ketamine, LSD, psilocybin, inhalant, illicit drug other or unspecified)
Concurrent non-opioid extramedical pharmaceutical use	not stated, present (based on the presence of at least one of the pharmaceutical groups coded for; non-opioid analgesics, benzodiazepines, anti-depressants, anti-psychotics, anti-convulsants, opioid-dependence treatments, pharmaceutical stimulants, other medication)
Co-morbid mental health symptoms	not stated, present (based on the presence of at least one of; symptoms of anxiety, depression, psychosis, social / emotional distress, symptoms associated with disorders with clinical evidence, and mental health unspecified)
Co-morbid suicidal thoughts or behaviours	Not stated, present (based on the presence of at least one of; suicidal ideation, suicide attempt)
Co-morbid non-suicidal self-injury	Not stated, present (based on the presence of at least one of; threat of non-suicidal self-injury, non-suicidal self-is, non-suicidal self-injury)
Accidental overdose	Not stated, yes
Unknown intent overdose#	Not stated, yes
Past history of psychiatric issues	Not stated, present (based on the presence of at least one of; past history of mood disorder, psychosis, suicidal ideation, suicide attempt, alcohol and other drug misuse)
<p>^based on previous age categories used in studies of opioid use for pain (38). We will exclude cases where age is reported to be less than 12 due to the unclear intention of use in children of this age, consistent with previous research (39, 40).</p> <p>#(where information provided in the patient care records by the paramedic means that the coding team cannot determine if the overdose was accidental or if there was suicidal intent)</p> <p>∞The involvement of alcohol is coded as 'alcohol involved' and 'alcohol intoxication'. Attendances where the person has consumed alcohol, but the paramedic notes do not clearly indicate alcohol intoxication are coded as 'alcohol involved' and 'alcohol intoxication is a subset of 'alcohol involved'. The default code is for 'alcohol involved' unless the paramedic notes provide clear evidence of alcohol intoxication.</p>	

1
2
3 Figure Captions:
4

5 Figure 1- Overview of study processes and data sources (VIC = Victoria, NSW = New South Wales,
6 QLD = Queensland, TAS = Tasmania, ACT = Australian Capital Territory, NT = Northern Territory)
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Comparing rates and characteristics of ambulance attendances related to extramedical use of pharmaceutical opioids in Australia: a protocol for a retrospective observational study

Supplementary materials

Appendix A. Description of coder training and inter-rated reliability processes	2
Appendix B. Description of variables to be examined in association with pharmaceutical opioid-related ambulance attendances	3
References	8

For peer review only

Appendix A. Description of coder training and inter-rated reliability processes

Research Assistants undertake extensive and ongoing training to ensure coding is consistent. To assist with this, coding guides are utilised that detail categories, the process of classification, provide examples of typical attendance types, and examples of uncommon attendance types. When a new Research Assistant commences, they are first trained by senior researchers, and then paired with multiple experienced Research Assistants on a rotating basis, until they and their senior coding partner are confident of coding consistency. Senior researchers review attendances coded by new Research Assistants to ensure inter- and intra-coder reliability. In addition to training upon appointment, all Research Assistants participate in monthly ongoing training. This training covers issues like complex cases or the introduction of new variables. This training is completed with workshops and “dummy case exercises”.

On a day-to-day basis, if Research Assistants are not confident in coding a specific attendance, the attendance is escalated to a senior researcher for review (<1% of attendances). These review cases then feed into regular workshops, which are also used to identify common coding issues, and disseminate coding clarifications on an ongoing basis.

To maintain inter-coder validation, inter-rater review audits are completed by a senior researcher. These are used as a personal learning tool for Research Assistants, and to identify common issues that may need to be addressed across the coding team. As an example of inter-coder validation, results of the most recent coding audit are described below: A maximum of 90 previously coded attendances per Research Assistant were extracted, from the Victoria Quarter 1, 2017 dataset. The 90 attendances met 26 criteria for case-classification. Each Research Assistant then re-coded a random selection of attendances for which they were not the original coder. At that time, there were 23 individual Research Assistants, and the attendances they re-coded came from an average of 9 ± 3 (mean \pm standard deviation) other Research Assistants. A total of 1,718 attendances were re-coded, which meant 221,622 AOD variables were re-coded, of which only 470 differences were identified (i.e. 0.2% of variables). Differences were systematically identified, and reviewed by a senior researcher for personalised feedback to each Research Assistant and then followed up with systemic team training.

Appendix B. Description of variables to be examined in association with pharmaceutical opioid-related ambulance attendances

Variable	Description	Transformations/ intended aggregations and final response options used for analyses	Data source
Presenting Glasgow Coma Scale (GCS)	The Glasgow Coma Scale [1] is a 13 point (range 3-15) scale that assesses injured patients' level of consciousness. The GCS's overall reliability is adequate [2], and it is used by prehospital and hospital staff in most English speaking countries and most of Europe [3].	Response Options: 3 (non-responsive), 4-8 (severe impairment), 9-12 (moderate impairment), 13-15 (minor-no impairment), consistent with previous research with substance-related attendances [4, 5]. This study further isolated the "non-responsive" group (GCS=3) who would not have responded at all, to any of the three components of eye, verbal and motor response to external stimuli.	GCS score is assessed and directly entered into the ePCR by trained paramedics.
Presenting respiratory rate (breaths per minute)	There are not clearly defined standard grouping for respiration rate. However, the normal adult respiration rate is generally considered 12-20 breaths per minute [6], and high doses of opioids depress ventilation [7]. The dispatch protocols from the ambulance systems involved in this study class less than 6 breaths a minute as ineffective breathing.	Grouped into three response Options: <6, 6-12, >12	Respiration rate is assessed and directly entered into the ePCR by trained paramedics.
Transport to hospital	Transport outcome relating to attendance	Response Options: Not transported, transported	Outcome of attendance directly entered into the ePCR as a binary variable by trained paramedics and validated by trained coders after reviewing free-text fields.
Naloxone administered: not stated, yes	Naloxone is an opioid antagonist that reverses the effects of opioid overdose [7].	Response Options: Not stated, yes	Binary variable in ePCR, entered by trained paramedic and validated by trained coders after free-text fields.

Naloxone response: not effective, effective		Response Options: Not effective, effective	Binary variable entered by trained paramedic and validated by coders checking free text field on clinical descriptions e.g. GCS ~3 returning to GCS ~15.
Sex of patient	Sex is coded into male, female and non-binary options, however states vary on how they to record non-binary gender. Codiers validate and re-code gender as male, female, and other/unknown.	For these analyses response options were coded as: Male (0), female (1), other/unknown (9), missing (.) All patients regardless of sex included in analyses related to Aim 1 (rates) and Aim 3 (context of presentation). Those with known sex will be included in the analyses for Aim 2, with missing data quantified.	Four options in the ePCR entered by paramedics, missing data may be coded based on information in free-text.
Age of patient	Our categories were based on previous age categories used in studies of opioid use for pain which were <55, 55-65 and 65+ [8] to enable comparison. In Australia, most overdoses occur in adults with the peak age category in 35-44 [9] and increases observed in older age categories. For this reason we have split those aged from 12 -54 into two categories, 12-34 and 35-55, to enable comparison with national overdose trends. Smaller age groups are not possible due to low rates in younger adults leading to potential censoring of cells. We will exclude cases where age is reported to be less than 12 due to the unclear intention of use in children of this age, consistent with previous research [10, 11].	Response Options: 12-34, 35-54, 55-65 (nearing retirement age) and 65+	DOB is entered by paramedic, missing data may be coded based on information in free-text.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

<p>Socio-economic status based on residential postcode</p>	<p>The Socio-Economic Indexes for Areas (SEIFA) ranks geographic areas according to relative socio-economic advantage and disadvantage [12, 13]. The SEIFA is one of the most commonly used measures for socioeconomic status in Australia, and it has been updated every 10 years with Census data since 1986 [14].</p> <p>Lower scores indicate more disadvantaged areas and higher scores indicate more advantaged areas.</p>	<p>Response Options: Quintile 1-5.</p> <p>At Turning Point, the postcode from the ePCR is linked to the Australian Bureau of Statistics' (ABS) database of SEIFA ranks by postcode (2016), and then these ranks were aggregated into quintiles specific to each state.</p>	<p>Postcode is entered by paramedic</p>
<p>Concurrent alcohol involvement</p>	<p>Concurrent alcohol use is captured because the simultaneous use of multiple depressant drugs (e.g. opioids, alcohol and heroin) increase the risk of overdose [15].</p>	<p>Response Options: Not stated, alcohol involved but no evidence of intoxication, alcohol intoxication.</p> <p>The involvement of alcohol is coded as 'alcohol involved' and 'alcohol intoxication'. Attendances where the person has consumed alcohol, but the paramedic notes do not clearly indicate alcohol intoxication are coded as 'alcohol involved', and 'alcohol intoxication' is a subset of 'alcohol involved'. The default code is for 'alcohol involved' unless the paramedic notes provide clear evidence of alcohol intoxication. For this study, these cases were recoded into exclusive categories – not stated, alcohol involved but no evidence of intoxication and alcohol intoxication.</p>	<p>Coders extract information about alcohol involvement from free-text fields as 'not stated' or 'alcohol involved'. There is a subcategory of 'intoxication' under 'alcohol involved'.</p>

1 2 3 4 5 6	Concurrent heroin involvement	Response Options: Not stated, present	Analysed as binary coded variable.	Coders extract information about heroin involvement from free-text fields and code.
7 8 9 10 11 12 13	Concurrent illicit drug use (excluding heroin)	Response Options: Not stated, present (based on the presence of at least one of the illicit drugs coded for; meth(amphetamine), cannabis, synthetic cannabinoids, emerging psychoactive substances, cocaine, MDMA, GHB, ketamine, LSD, psilocybin, inhalant, illicit drug other or unspecified)	Not stated/ present if any one of the illicit substances listed are reported as being used in the ePCR	Coders extract information about illicit drug involvement from free-text fields and code.
14 15 16 17 18 19 20 21 22	Concurrent non-opioid extramedical pharmaceutical use	Response Options: Not stated, extramedical use present (based on the presence of at least one of the pharmaceutical groups coded for; non-opioid analgesics, benzodiazepines, anti-depressants, anti-psychotics, anti-convulsants, opioid-dependence treatments, pharmaceutical stimulants, other medication)	Not stated/ present if any one of the pharmaceutical drugs listed are reported in the ePCR	Coders extract information about extramedical use of pharmaceutical drugs from free-text fields and code.
23 24 25 26 27 28 29 30 31 32 33	Co-morbid mental health symptoms	Response Options: Not stated, present (based on the presence of at least one of; symptoms of anxiety, depression, psychosis, social / emotional distress, symptoms associated with disorders with clinical evidence, and mental health unspecified). Symptomology is reported rather than diagnoses, as paramedics do not diagnose mental illness.	Recorded as binary option of not stated/ present if any one co-morbid symptoms listed are reported in the ePCR	Coders extract information from free-text fields and code.
34 35 36	Co-morbid suicidal thoughts or behaviours	Response Options: Not stated, present (based on the presence of at least one of; suicidal ideation, suicide, suicide attempt)	Recorded as binary option of not stated/ present if any one co-morbid suicidal thoughts or behaviours listed are reported in the ePCR	Coders extract information from free-text fields and code.
37 38 39 40 41 42	Co-morbid non-suicidal self-injury	Response Options: Not stated, present (based on the presence of at least one of;	Recorded as binary variable of not stated or present based on either threat of non-suicidal	Coders extract information from free-text fields and code.

	threat of non-suicidal self-injury, non-suicidal self-injury)	self-injury or non-suicidal self-injury documented in the ePCR	
Unintentional alcohol and other drug overdose	Where information provided in the patient care records by the paramedic suggests that the person did not intend to die (though they may have intended to take the substance). Overdose (also referred to as <i>AOD poisoning</i>) determined using GCS < 9 or 10x dose (for pharmaceuticals), however must also be evidence available to suggest poisoning was unintentional to be coded as yes.	Recorded as binary variable of not stated, yes	Coders extract information from free-text fields and code.
Undetermined intent overdose	Where information provided in the patient care records by the paramedic means that the coding team cannot determine if the overdose was unintentional (also referred to as ' <i>accidental</i> ') or if there was suicidal intent.	Response Options: Not stated, yes	Coders extract information from free-text fields and code.
Past history of psychiatric issues	Response Options: Not stated, present (based on the presence of at least one of; past history of mood disorder (including anxiety, depression, PTSD, Bipolar and OCD), psychosis, suicidal ideation, suicide attempt, alcohol and other drug misuse).	Response Options: Not stated, present	Coders extract information from free-text fields and code.

References

1. Teasdale, G. and B. Jennett, *Assessment of coma and impaired consciousness: A Practical Scale*. The Lancet, 1974. **304**(7872): p. 81-84.
2. Reith, F., et al., *The reliability of the Glasgow Coma Scale: a systematic review*. Intensive Care Medicine, 2016. **42**(1): p. 3-15.
3. Barlow, P., *A practical review of the Glasgow Coma Scale and Score*. The Surgeon, 2012. **10**(2): p. 114-119.
4. Dietze, P.M., et al., *Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria*. Med J Aust, 2008. **188**(12): p. 709-11.
5. Nielsen, S., et al., *Methadone and Buprenorphine related ambulance attendances: A population-based indicator of adverse events*. Journal of Substance Abuse Treatment, 2008. **35**(4): p. 457-461.
6. Flenady, T., T. Dwyer, and J. Applegarth, *Accurate respiratory rates count: So should you!* Australas Emerg Nurs J, 2017. **20**(1): p. 45-47.
7. Merlin, M.A., et al., *Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses*. The American Journal of Emergency Medicine, 2010. **28**(3): p. 296-303.
8. Campbell, G., et al., *Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic non-cancer pain: do different measures identify the same patients?* Pain. **In Press**(Accepted March 1, 2016).
9. Australian Institute for Health and Welfare, *Opioid harm in Australia and comparisons between Australia and Canada*. 2018.
10. Rhodes, A.E., et al., *Age-sex differences in medicinal self-poisonings: a population-based study of deliberate intent and medical severity*. Soc Psychiatry Psychiatr Epidemiol, 2008. **43**(8): p. 642-52.
11. Gunnell, D., D. Ho, and V. Murray, *Medical management of deliberate drug overdose: a neglected area for suicide prevention?* Emergency medicine journal : EMJ, 2004. **21**(1): p. 35-38.
12. Australian Bureau of Statistics, *2033.0.55.001 - Census of Population and Housing: Socio-Economic Indexes for Areas (SEIFA), Australia, 2016*. Canberra. . 2018.
13. Australian Bureau of Statistics. *Socio-Economic Indexes for Areas*. 2018; Available from: <https://www.abs.gov.au/websitedbs/censushome.nsf/home/seifa>.
14. Australian Bureau of Statistics, *Measures of Socioeconomic Status*. 2011.
15. Dietze, P., et al., *When is a little knowledge dangerous?: Circumstances of recent heroin overdose and links to knowledge of overdose risk factors*. Drug and Alcohol Dependence, 2006. **84**(3): p. 223-230.